Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
Feasibility Evaluation of Daily Disposable Toric Soft Contact Lenses Manufactured with an 
Alternative Hydration Process 
Protocol CR-6482   
Version: 2.0    
Date: 27 June 2022  
Investigational Products: Test: ACUVUE® OASYS 1-Day for ASTIGMATISM (AO1DfA) 
manufactured with propylene glycol hydration. Control: currently marketed AO1DfA with 
standard manufacturing process  
Keywords: Astigmatism, ACUVUE® OASYS 1-Day for Astigmatism, senofilcon A, daily 
wear, daily disposable, dispensing, Single use Eye-Cept® Rewetting Drops, LacriPure Saline 
Solution, ScleralFil Pres ervative Free Saline Solution, CLUE  comfort, CLUE vision, CLUE 
handling, logMAR visual acu ity, rotation performance. 
Statement of Compliance to protocol, GCP and applicable reg ulatory guidelines: 
This trial will be conducted in compliance with the protocol, ISO 14155:2020,1 the 
International Council for Harmonization Good Clinical Practice E6(R2) (ICH GCP),2 the 
Declaration of Helsinki,3 and all applicable re gulatory requirements. 
Confidentiality Statement: 
This document contains confidential information, which shoul d not be copied, referred to, 
released or published without  written approval from Johnson & Johnson Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee approval and informed consent, or as required by International, Federal and State Laws, as app licable. Persons to whom this information is 
disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of Johnson & Johnson Vision 
Care, Inc. Any supplemental information that  may be added to this document is also 
confidential and proprie tary to Johnson & Johnson Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document. 
CR-6482, v 2.0  
Page 1 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
TABLE OF CONTENTS  
PROTOCOL TITLE, NUMBER, VERSION AND DATE...................................................... 6  
SPONSOR NAME AND ADDRESS ....................................................................................... 6  
MEDICAL MONITOR ............................................................................................................. 6  
AUTHORIZED SIGNATURES ............................................................................................... 7  
CHANGE HISTORY................................................................................................................ 8  
SYNOPSIS ...................................................................................................................... .......... 9  
COMMONLY USED ABBREVIATIONS, A CRONYMS AND DEFINITIONS OF TERMS
................................................................................................................................................. 15  
1. INTRODUCTION AND BACKGROUND ................................................................... 16  
1.1. Name and Descriptions of Investigational Products ................................................ 16  
1.2. Intended Use of Inve stigational Products................................................................. 16  
1.3. Summary of Findings from Nonclinical Studies ...................................................... 16  
1.4. Summary of Known Risks and Benefits to Human Subjects ................................... 16  
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical 
Study 17  
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES ...................................... 17  
2.1. Objectives ................................................................................................................. 17  
2.2. Endpoints .................................................................................................................. 17  
2.3. Hypotheses ............................................................................................................... 18  
3. TARGETED STUDY POPULATION ........................................................................... 18  
3.1. General Characteristics ............................................................................................ 18  
3.2. Inclusion Criteria ...................................................................................................... 18  
3.3. Exclusion Criteria ..................................................................................................... 18  
3.4. Enrollment Strategy.................................................................................................. 19  
4. STUDY DESIGN AND RATIONALE .......................................................................... 20  
4.1. Description of Study Design .................................................................................... 20  
4.2. Study Design Rationale ............................................................................................ 20  
4.3. Enrollment Target and Study Duration .................................................................... 20  
5. TEST ARTICLE ALLOCATION AND MASKING ..................................................... 21  
5.1. Test Article Allocation ............................................................................................. 21  
5.2. Masking .................................................................................................................... 21  
5.3. Procedures for Maintaining and Breaking the Masking........................................... 22  
6. STUDY INTERVENTION ............................................................................................. 22  
CR-6482, v 2.0  
Page 2 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
6.1. Identity of Test Articles............................................................................................ 22  
6.2. Ancillary Supplies/Products ..................................................................................... 23  
6.3. Administration of Test Articles ................................................................................ 24  
6.4. Packaging and Labeling ........................................................................................... 24  
6.5. Storage Conditions ................................................................................................... 24  
6.6. Collection and Storage of Samples .......................................................................... 25  
6.7. Accountability of Test Articles ................................................................................ 25  
7. STUDY EVALUATIONS .............................................................................................. 26  
7.1. Time and Event Schedule ......................................................................................... 26  
7.2. Detailed Study Procedures ....................................................................................... 27  
VISIT 1 ........................................................................................................................... 27  
VISIT 2 ........................................................................................................................... 34  
VISIT 3 ........................................................................................................................... 36  
VISIT 4 ........................................................................................................................... 37  
FINAL EVALUATION .................................................................................................. 38  
7.3. Unscheduled Visits ................................................................................................... 39  
7.4. Laboratory Procedures ............................................................................................. 40  
8. SUBJECTS COMPLETION/WITHDRAWAL.............................................................. 41  
8.1. Completion Criteria .................................................................................................. 41  
8.2. Withdrawal/Discontinua tion from the Study ........................................................... 41  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. 42  
9.1. Systemic Medications .............................................................................................. 42  
10. DEVIATIONS FROM THE PROTOCOL .................................................................. 43  
11. STUDY TERMINATION ........................................................................................... 44  
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS .............. 45  
13. ADVERSE EVENTS ................................................................................................... 46  
13.1.  Definitions and Classifications ............................................................................. 46  
13.2.  Assessing Adverse Events .................................................................................... 48  
13.2.1.  Causality Assessment .................................................................................... 49  
13.2.2.  Severity Assessment ...................................................................................... 49  
13.3.  Documentation and Follow-Up of Adverse Events .............................................. 49  
13.4.  Reporting Adverse Events .................................................................................... 51  
13.4.1.  Reporting Adverse Events to Sponsor .......................................................... 51  
CR-6482, v 2.0  
Page 3 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
13.4.2.  Reporting Adverse Events to the Respons ible IEC/IRB and Health Authorities
 52  
13.5.  Event of Special Interest ....................................................................................... 52  
13.6.  Reporting of Pr egnancy ........................................................................................ 52  
14. STATISTICAL METHODS ........................................................................................ 52  
14.1.  General Considerations ......................................................................................... 52  
14.2.  Sample Size Justification ...................................................................................... 53  
14.3.  Analysis Populations ............................................................................................ 53  
14.4.  Level of Statistical Significance ........................................................................... 53  
14.5.  Primary Analysis .................................................................................................. 53  
14.6.  Secondary Analysis .............................................................................................. 53  
14.7.  Other Exploratory Analysis .................................................................................. 54  
14.8.  Interim Analysis ................................................................................................... 54  
14.9.  Procedure for Handling Missi ng Data and Drop-Outs ......................................... 54  
14.10.  Procedure for Reporting Deviati ons from Statistical Plan ................................... 54  
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING ................................ 54  
15.1.  Electronic Case Report Form/Data Collection ..................................................... 54  
15.2.  Subject Record ...................................................................................................... 55  
15.3.  Trial Registration on Cl inicalTrials.gov ............................................................... 55  
16. DATA MANAGEMENT............................................................................................. 55  
16.1.  Access to Source Data/Document ........................................................................ 55  
16.2.  Confidentiality of Information.............................................................................. 56  
16.3.  Data Quality Assurance ........................................................................................ 56  
16.4.  Data Monitoring Committee (DMC) .................................................................... 56  
17. CLINICAL MONITORING ........................................................................................ 56  
18. ETHICAL AND REGULATORY ASPECTS ............................................................ 57  
18.1.  Study-Specific Design Considerations ................................................................. 57  
18.2.  Investigator Responsibility ................................................................................... 57  
18.3.  Independent Ethics Committee or Ins titutional Review Board (IEC/IRB) .......... 57  
18.4.  Informed Consent ................................................................................................. 59  
18.5.  Privacy of Personal Data ...................................................................................... 59  
19. STUDY RECORD RETENTION................................................................................ 60  
20. FINANCIAL CONSIDERATIONS ............................................................................ 61  
CR-6482, v 2.0  
Page 4 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
21. PUBLICATION ........................................................................................................... 61  
22. REFERENCES ............................................................................................................ 61  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) ..... 63  
APPENDIX B: PATIENT INSTRUCTION GUIDE  ............................................................ 72  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ......................................... 73  
APPENDIX D:  .................................... 102  
LENS FITTING CHARACTERISTICS ............................................................. 103  
SUBJECT REPORTED OCULAR SYMPTOMS .............................................. 109  
DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
............................................................................................................................................... 111  
BIOMICROSCOPY SCALE .............................................................................. 117  
DISTANCE AND NEAR VISUAL ACUITY EVALUATION ......................... 123  
TORIC FIT EVALUATION ............................................................................... 128  
ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE ...... 133  
PATIENT REPORTED OUTCOMES................................................................ 137  
LENS INSERTION AND REMOVAL .............................................................. 139  
VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING ....................................................................................................................... ....... 142  
APPENDIX E: GUIDELINES FOR COVID-19 RISK MITIGATION............................... 151  
PROTOCOL COMPLIANCE INVESTI GATOR(S) SIGNATURE PAGE ........................ 163  
 
LIST OF TABLES 
Table 1: Test Articles ........................................................................................................ ...... 23  
Table 2: Ancillary Supplies ................................................................................................... . 24 
Table 3: Time and Events ...................................................................................................... . 26 
Table 4: Disallowed syst emic medications ............................................................................. 42  
Table 5: Disallowed syst emic antihistamines ......................................................................... 43  
Table 6: Examples of major and minor protocol deviations ................................................... 44  
 
LIST OF FIGURES 
Figure 1: Study Flowchart ..................................................................................................... . 14 
    
CR-6482, v 2.0  
Page 5 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
SYNOPSIS  
Protocol Title Feasibility Evaluation of Daily Disposable Toric Soft Contact 
Lenses Manufactured with an Alternative Hydration Process 
Sponsor JJVC, 7500 Centurion Pa rkway, Jacksonville, FL  32256 
Clinical Phase Clinical trial phase: Feasibility  
Design control phase: Post -launch design change 
Trial Registration This study will be registered on ClinicalTrials.gov by the 
Sponsor 
Test Article(s) Inves tigational Products:  
Test: ACUVUE® OASYS 1-Day for ASTIGMATISM 
(AO1DfA) Soft Contact Lens es produced with propylene 
glycol (PG) hydration.  
Approved Products:  
Control: AO1DfA Soft Contact Lenses produced with the current commercial manufacturing process.  
Wear and Replacement Schedules Wear Schedule: daily wear Replacement Schedule: daily disposable 
Objectives  Primary Objective: 
To evaluate the incidence of grade 3 or higher biomicroscopy 
findings following a 7(±2) day wear period for AO1DfA contact lenses produced with propylene glycol (PG) hydration relative to the same design produced using the current commercial manufact uring process. 
 Exploratory Objectives: To evaluate the subjective comfort, vision and handling, visual acuity, and rotational performance over a 7(±2) day wear period for AO1DfA contact lenses produced with propylene glycol (PG) hydration relative to the same design produced using the current commercial manufacturing 
process. 
CR-6482, v 2.0  
Page 9 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
Study Endpoints Primary endpoint: 
x Incidence of grade 3 or higher biomicroscopy findings 
using the FDA grading s cale following a 7(±2) day 
wear period  
 Observational endpoints (efficacy): 
x Subjective comfort, vision and handling at fitting and following a 7(±2) day wear period using the CLUE questionnaire 
x High-luminance, high-contrast  (HLHC) visual acuity 
in logMAR measured using ETDRS charts at follow-up 
x Lens orientation at 1 minut e and 3 minutes following 
insertion at fitting 
x Mean and standard deviation of settled lens orientation 
calculated from repeated measures of settled lens 
orientation at fitting and follow-up visits  
 Observational endpoints (safety): 
x Adverse events 
 All endpoints will be summarized using descriptive statistics 
only; no formal hypothesis testing is planned.  
Study Design This is a bilateral, di spensing, randomized, controlled, double 
masked, 2×2 cross-over study. E ach subject will be randomly 
assigned to one of two wear  sequences (test followed by 
control or control followed by test). Each wear period will be 7(±2) days, with a 7(±2) day washout period between wear periods.   There will be a total of 4 visits: Visit 1: Screening, baseline evaluation and lens fit #1  
Visit 2: Follow-up evaluation for first lens Visit 3: Continuance, lens fit #2 Visit 4: Follow-up evaluation for second lens  See the flow chart at the end of the synopsis table for the 
schematic of the study visits  and procedures of main 
observations (Figure 1). 
Sample Size This study will have an enrollment target of approximately 66 
subjects, with a target of at least 60 to complete (assuming a dropout rate of 10%).  
Study Duration Total study duration in cluding the enrollment period is 
anticipated to be approximately 8 weeks.  
CR-6482, v 2.0  
Page 10 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
Anticipated Study 
Population Subjects will be habitual soft contact lens wearers with bilateral astigmatism who are between 18 and 39 years of age (inclusive).  
Eligibility Criteria - Inclusion Potential subjects must satisfy of all the following criteria to be enrolled in the study.  Inclusion Criteria following Screening The subject must: 
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.  
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 
3. Be between 18 and 39 (inclusive) years of age at the time of screening. 
4. By self-report, habitually wear soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 2 days per week during the past month. 
5. Possess a wearable pair of spectacles that provide correction for distance vision. 
 Inclusion Criteria at Baseline Evaluation The subject must: 
6. In both eyes, have astigmatic refractive error suitable for correction with the toric contact lens powers available in this study: 
a. Sphere powers (DS) -1.50 through -4.00 (inclusive) in 
0.25 steps 
b. Cylinder powers (DC) -0.75 and -1.25 
c. Axes (°) 170, 180, 10, 80, 90, 100 
7. Have best corrected monocular distance visual acuity of 
20/30 or better in each eye. 
CR-6482, v 2.0  
Page 11 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
Eligibility Criteria – 
Exclusion Potential subjects who meet any of the following criteria will be excluded from participating in the study:   Exclusion Criteria following Screening The subject must not: 
1. Be currently pregnant or lactating. 
2. Be diabetic. 
3. Be currently using any ocular medications or have an ocular infection of any type. 
4. By self-report, have any ocular or systemic disease, allergies, infection, or us e of medication that might 
contraindicate or interfere wi th contact lens wear, or 
otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressi ve disease (e.g., Human 
Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögr en’s syndrome), or history 
of serious mental illness or seizures. See section 9.1 for 
additional details regard ing excluded systemic 
medications.  
5. Have habitually worn rigid gas permeable (RGP) lenses, 
orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months. 
6. Be currently wearing monovisi on or multifocal contact 
lenses. 
7. Be currently wearing lenses in an extended wear modality. 
8. Have a history of stra bismus or amblyopia. 
9. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, pare nt, grandparent, grandchild 
or sibling of the employee or their spouse) of the clinical 
site. 
10. Have participated in a contact lens or lens care product clinical trial within 7 da ys prior to study enrollment. 
 Exclusion Criteria at Baseline Evaluation The subject must not: 
11. Have clinically significant (grade 3 or higher on the FDA 
grading scale) slit lamp fi ndings (e.g., corneal edema, 
neovascularization or staining, tarsal abnormalities or bulbar injection) or other co rneal or ocular disease or 
abnormalities that contraindicate contact lens wear or may 
otherwise compromise study endpoints (including entropion, ectropion, chalazia, re current styes, glaucoma, 
CR-6482, v 2.0  
Page 12 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
history of recurrent corneal er osions, aphakia, moderate or 
above corneal distortion, herpetic keratitis).  
12. Have fluctuations in vision due  to clinically significant dry 
eye or other ocular conditions.  
13. Have had or have planned (within the study period) any 
ocular or intraocular surgery (e.g., radial keratotomy, 
PRK, LASIK, iridotomy, re tinal laser photocoagulation, 
etc.). 
Disallowed Medications/Interventions  Subjects will not be eligible to enroll if they are taking any ocular medications, or any syst emic medications that would 
normally contraindicate contact lens wear or may otherwise 
compromise study endpoints. See section 9.1 for details regarding disallowed sy stemic medications.  
Measurements and Procedures Key procedures associated with  the endpoints for this study 
will include: 
- Examination of the anterior segment using a slit lamp biomicroscope and grading findings using the FDA grading scale 
- Completion of the CLUE que stionnaire at fitting and 
follow-up 
- Measurement of HLHC VA using ETDRS charts at follow-up 
- Measurement of lens orienta tion at 1 minute and 3 minutes 
following insertion, and following lens settling 
Microbiology or Other Laboratory Testing Not applicable for this study. 
Study Termination The occurrence of an  Unanticipated Adverse Device Effect 
(UADE) or Serious Adverse Event (SAE) for which a causal relationship to a test article ca nnot be ruled out, will result in 
stopping further dispensing inves tigational product. In the 
event of a UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of  subject(s) and may discuss 
this with the Principal Investigator before any further subjects are enrolled. 
Ancillary Supplies/ Study-Specific Materials Lens cases, fluorescein strips  and preservative-free rewetting 
drops / artificial te ars will be supplied for use as needed.  
Principal Investigator(s) and Study Institution(s)/Site(s) A full list of Principal Investigators, clinical sites, and institutions is kept separately from the St udy Protocol and is 
included in the study Trial Master File. 
   
CR-6482, v 2.0  
Page 13 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
Figure 1: Study Flowchart 
Visit 1: Screening 
Statement of Informed Consent 
Demographics 
Medical History & Concomitant Medications 
Habitual Contact Lens Information 
Eligibility at Screening 
Baseline Evaluation 
Subject Reported Ocular Symptoms 
Entrance visual acuity 
Spherocylindrical refraction and distance visual acuity 
Slit lamp biomicroscopy findings Eligibility after Baseline 
Baseline CLUE questionnaire (habitual lenses) 
Lens Fitting (#1 through #2) 
Lens assignment and insertion
Timed rotation assessments, lens settling 
Toric and general fit assessment 
Spherical over-refraction, modification if required 
CLUE post-fit questionnaire 
Additional samples of toric lens orientation  
Lenses dis pensed for 7 r2 days 
Follow-up (#1 through #2) 
CLUE follow-up questionnaire 
ETDRS HLHC visual acuity 
Record lens orientation 
Additional samples of toric lens orientation  
Lens removal Biomicroscopy 
Schedule next visit Continuance 
Review med history and medications 
Subject reported ocular symptoms 
Entrance VA and biomicroscopy 
Confirm continuin g eligibilit y 
Final Evaluation  
Spherocylindrical refraction 
Completion status 
Biomicroscopy (if discontinued early) After follow-up #1 
al EvaluationAfter follow-up #2Washout Period 
A washout period of 7 r2 days duration 
will be observed between wear periods 
CR-6482, v 2.0  
Page 14 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF 
TERMS 
ADE   Adverse Device Effect 
ADHD   Attention Deficit Hyperactivity Disorder 
AE   Adverse Event/Adverse Experience AO1DfA ACUVUE
® OASYS 1-DAY with HydraLuxe™ TECHNOLOGY for 
ASTIGMATISM 
BSCVA  Best Spectacle Corrected Visual Acuity CFR   Code of Federal Regulations CLUE   Contact Lens User Experience COM   Clinical Operations Manager CRA   Clinical Research Associate CRF   Case Report Form 
CRO   Contract Research Organization 
    
D   Diopter 
DMC   Data Monitoring Committee eCRF   Electronic Case Report Form EDC   Electronic Data Capture ETDRS  Early Treatment Di abetic Retinopathy Study 
FDA   Food and Drug Administration GCP   Good Clinical Practice HIPAA  Health Insurance Portability and Accountability Act HIV   Human Immunodeficiency Virus IB   Investigator’s Brochure ICH   The International Council for Harmonization IEC   Independent Ethics Committee IRB   Institutional Review Board ISO   International Organization for Standardization ITT   Intent-to-Treat JJVC   Johnson & Johnson Vision Care, Inc. LASIK   Laser-Assisted in Situ Keratomileusis LogMAR  Logarithm of Minimal Angle of Resolution OD   Right Eye OS   Left Eye OU   Both Eyes PIG   Patient Instruction Guide PQC   Product Qu ality Complaint 
PRK   Photorefractive Keratectomy PRO   Patient Reported Outcome QA   Quality Assurance SAE   Serious Adverse Event/Serious Adverse Experience SAS   Statistical Analysis System SD   Standard Deviation 
CR-6482, v 2.0  
Page 15 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
UADE   Unanticipated Adverse Device Effect 
USADE  Unanticipated Serious Adverse Device Effect VA   Visual Acuity 
1. INTRODUCTION AND BACKGROUND 
The AO1DfA lens is a daily wear, daily disposab le toric soft contact lens manufactured in 
senofilcon A. This lens is currently produced with isopropyl alcohol (IPA) hydration, whereas 
the spherical counterpart to this lens (ACUVUE
® OASYS 1-Day Contact Lenses) is 
manufactured with propylene  glycol (PG) hydration.  
 
The purpose of this study is to evaluate the fe asibility of manufacturing AO1DfA lenses using 
PG hydration with comparable clinical perfor mance to those made with the current IPA 
hydration process.  
1.1. Name and Descriptions of Investigational Products  
This study will evaluate the AO1DfA lens design produced using PG hydration against 
AO1DfA lenses produced using the standard IPA hydration process as control. Further details about the test articles are found in  section 6.1 of this protocol. 
1.2. Intended Use of Investigational Products 
The intended use of the investig ational product is the correction of astigmatism and associated 
myopic refractive error. Study lenses will be worn  bilaterally in a daily wear, daily disposable 
modality for at least 8 hours per day. Each wear period will be 7±2 (i.e., 5 to 9) days in duration, and subjects will wear lenses for at least 5 days per week during each wear period. Two wear periods will be completed, with a washout pe riod of 7±2 days between the wear periods. 
1.3. Summary of Findings fr om Nonclinical Studies 
All previous pre-clinical findings were deemed satisfactory prior to proceeding with clinical 
trials on humans. For the most comprehensiv e nonclinical informat ion regarding AO1DfA 
lenses manufactured with PG hydration refer to  the latest version of the Investigator's 
Brochure.
5 
1.4. Summary of Known Risks and Benefits to Human Subjects 
The anticipated clinical benefit of the investigational lenses will be the correction of refractive error. The risks associated with use of the inves tigational lenses are consid ered to be equivalent 
to those associated with other commercial soft contact lenses worn in the same modality (i.e. daily disposable).   
 For the most comprehensive risk and bene fit information regarding AO1DfA lenses 
manufactured with PG hydration refer to the latest version of the  Investigator's Brochure.
5 
Comprehensive risk and benefit information regarding AO1DfA lenses produced using the 
current manufacturing process is included in  the AO1DfA package insert (Appendix C).   
CR-6482, v 2.0  
Page 16 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed 
Clinical Study 
The AO1DfA lens (manufactured with IPA hydrati on) has an extensive safety history and has 
been marketed in the US and Europe since 2017 with no incidence of recalls. The spherical 
counterpart to this lens, ACUVUE® OASYS 1-Day (AO1D) manufactured with PG hydration, 
has been marketed commercially since 2016 and also has no history of recalls.   AO1DfA lenses manufactured w ith PG hydration were previ ously evaluated in  over 
a 5- to 7-day dispensing period.
6 Out of the 121 subjects that we re randomized, two ocular and 
two non-ocular adverse events were reported, all of which were cons idered unrelated or 
doubted to be related to the investigational lenses.   Further information regarding literature references and prior data relevant to the test and 
control lenses can be found in  the Investigator's Brochure
5 and AO1DfA package insert 
(Appendix  C), respectively. 
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES 
2.1. Objectives  
Primary Objective: 
To evaluate the incidence of grade 3 or hi gher biomicroscopy findings following a 7(±2) day 
wear period for AO1DfA contact lenses produc ed with propylene glycol (PG) hydration 
relative to the same design produced using th e current commercial manufacturing process. 
 Exploratory Objectives: To evaluate the subjective comfort, visi on and handling, visual acuity, and rotational 
performance over a 7(±2) day wear period for AO1DfA contact lenses produced with 
propylene glycol (PG) hydration relative to the same design produced using the current commercial manufacturing process. 
2.2. Endpoints  
Primary endpoint: 
x Incidence of grade 3 or higher biomicrosc opy findings using the FDA grading scale 
following a 7(±2) day wear period  
 Observational endpoints (efficacy): 
x Subjective comfort, vision and handling at fitting and following a 7(±2) day wear period using the CLUE questionnaire 
x High-luminance, high-contrast (HLHC) visu al acuity in logMAR measured using 
ETDRS charts at follow-up 
x Lens orientation at 1 minute and 3 minutes following insertion at fitting 
x Mean and standard deviation of settled lens orientation calculated from repeated measures of settled lens orientation at fitting and follow-up visits  
CR-6482, v 2.0  
Page 17 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 
Observational endpoints (safety): 
x Adverse events 
2.3. Hypotheses 
All endpoints will be summarized using descrip tive statistics only; no formal hypothesis testing 
will be conducted.  
3. TARGETED STUDY POPULATION 
3.1. General Characteristics  
The target population for this study will be healt hy adult soft contact lens wearers between 18 
and 39 years of age with binocular myopic astigmatism.   
3.2. Inclusion Criteria 
Potential subjects must satisfy all of the fo llowing criteria to be enrolled in the study: 
 Inclusion Criteria at Screening The subject must: 
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.  
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 
3. Be between 18 and 39 (inclusive) years of age at the time of screening. 
4. By self-report, habitually wear soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear pe r day, for a minimum of 2 days per week 
during the past month. 
5. Possess a wearable pair of spectacles that  provide correction for distance vision. 
 Inclusion Criteria at Baseline Evaluation The subject must: 
6. In both eyes, have astigmatic refractive error suitable for correction with the toric contact lens powers available in this study: 
a. Sphere powers (DS) -1.50 thr ough -4.00 (inclusive) in 0.25 steps 
b. Cylinder powers (DC) -0.75 and -1.25 
c. Axes (°) 170, 180, 10, 80, 90, 100 
7. Have best corrected monocular distance visu al acuity of 20/30 or better in each eye. 
3.3. Exclusion Criteria 
Potential subjects who meet any of the following criteria will be excluded from participating in the study:   Exclusion Criteria following Screening 
CR-6482, v 2.0  
Page 18 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
The subject must not: 
1. Be currently pregnant or lactating. 
2. Be diabetic. 
3. Be currently using any ocular medications or  have an ocular infection of any type. 
4. By self-report, have any ocular  or systemic disease, allergies, infection, or use of 
medication that might contraindicate or interfere with contact lens wear, or otherwise 
compromise study endpoints, including infecti ous disease (e.g., hepatitis, tuberculosis), 
contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s syndrome), or history of serious mental illness or seizures. See se ction 9.1 for additiona l details regarding 
excluded systemic medications.  
5. Have habitually worn rigid gas permeable  (RGP) lenses, orthokeratology lenses, or 
hybrid lenses (e.g. SynergEyes, Soft Perm) within the past 6 months. 
6. Be currently wearing monovision or multifocal contact lenses. 
7. Be currently wearing lenses in an extended wear modality. 
8. Have a history of stra bismus or amblyopia. 
9. Be an employee (e.g., Investigator, Coordi nator, Technician) or immediate family 
member of an employee (including partner, child, parent, grandpar ent, grandchild or 
sibling of the employee or their spouse) of the clinical site. 
10. Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment. 
 Exclusion Criteria at Baseline Evaluation The subject must not: 
11. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp 
findings (e.g., corneal edema, neovascularization or staini ng, tarsal abnormalities or 
bulbar injection) or other corneal or ocular disease or abnormalities  that contraindicate 
contact lens wear or may otherwise co mpromise study endpoints (including entropion, 
ectropion, chalazia, recurrent st yes, glaucoma, history of recurrent corneal erosions, 
aphakia, moderate or above cornea l distortion, herpe tic keratitis).  
12. Have fluctuations in vision due to clinically significant dry eye or other ocular 
conditions.  
13. Have had or have planned (within the study period)  any ocular or intraocular surgery 
(e.g., radial keratotomy, PRK, LASIK, iri dotomy, retinal laser photocoagulation, etc.).  
3.4. Enrollment Strategy 
Study subjects will be recruited from the Instituti on/clinical site’s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved materials.  
CR-6482, v 2.0  
Page 19 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
4. STUDY DESIGN AND RATIONALE 
4.1. Description of Study Design 
This will be a 4-visit, randomized, controlle d, double-masked, bilateral wear, dispensing, 2×2 
crossover study. Each subject will be randomized into one of two unique sequences to wear 
two different study lenses one at a time over tw o wear periods (test followed by control or 
control followed by test). During each wear peri od the lenses will be worn bilaterally for 1 
week (7r2 days) in a daily disposable modality. Study lenses will be worn for a minimum of 
8 hours per day and at least 5 days per week dur ing the wear period. Subj ective comfort, vision 
and handling will be asse ssed using the CLUE questionnaire at both fitting and follow-up visits 
for each wear period. HLHC VA will be asse ssed at the follow-up ev aluation using ETDRS 
charts. There will be a washout period of 7 r2 days duration between wear periods. Subjects 
will not have access to the study lenses  following completion of the protocol. 
4.2. Study Design Rationale 
A 2×2 crossover study design was chosen to allow efficient comparison of the test articles by 
allowing each subject to act as their own control. A washout pe riod will be included to mitigate 
any carryover effects.   
The prescribed wear schedule (7 r2 days, minimum of 8 hours per day, minimum of 5 days per 
week) was chosen as this is representative of a typical wear schedule for contact lens wearers.  
 The control lens will be AO1DfA manufacture d on commercial production lines using the 
standard IPA hydration process, thus the only diff erence between the test and control lenses in 
this study will be the hydration process.   The CLUE questionnaire was selected on the basi s of being the best available validated PRO 
tool for assessing subjective overall comfort, vision and handling of  soft contact lens wearers. 
 ETDRS charts will be used to measure visual acuity in logMAR units under high-luminance conditions using high-contrast charts. ETRDS charts were chosen on the basis of being 
considered the gold standard fo r logMAR visual acuity measurements in clinical trials.  
 The investigational lenses will be fitted by optometrists who are experienced at fitting soft contact lenses and will be evaluated by habitual contact lens wear ers in their standard wearing 
environment.  
4.3. Enrollment Target and Study Duration 
This study will have an enrollment target of approximately 66 subjects, with a target of at least 60 to complete. The study will be conducted at up to a pproximately 6 clinical sites, where the 
enrollment target for each site will be approximately 11 subjects. A subject will be considered enrolled upon signing of the informed consent form.    
CR-6482, v 2.0  
Page 20 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
There will be 4 visits in total per subject; total study duration including the enrollment period 
is expected to be approximately 8 weeks. S ubjects who are discontinued prior to the final 
evaluation may be replaced at the discretion of the study sponsor. The investigation will end 
at the time that the study data is hard locked. 
5. TEST ARTICLE ALLOCATION AND MASKING 
5.1. Test Article Allocation  
This study will be a randomized, double-maske d, 2×2 crossover design. Subjects will be 
randomized into one of 2 unique sequence groups (test/control or control/test) in a 1:1 
allocation ratio to wear two different study lens designs (test and control designs) one at a time 
bilaterally over 2 wear periods.   Use of the test articles will be randomized us ing a randomization scheme  supplied by the study 
biostatistician.  The randomized assignment of subjects will be performed at the first visit prior 
to the first fitting. Clinical sites will follow the randomization scheme provided and will not 
pre-select or assign subjects. The following mu st have occurred prior to randomization: 
x Informed consent must have been obtained 
x The subject must have met all inclusion and exclusion criteria 
x The subject history and baseline information must have been collected 
 
Randomly permuted block randomization will be used to avoid bias in the assignment of subjects to treatment and to enhance the validity of statistical comparisons across treatment groups.  When dispensing test articles, the followi ng steps should be followed to maintain 
randomization codes: 
1. Investigator or designee (documented on the Delegation Log) will consult the 
randomization scheme (lens fitting schedule) to obtain the test article assignment for that subject prior to dispensing. 
2. Investigator or designee will record the subject’s number on the appropriate line of the randomization scheme (lens fitting schedule).  
3. Investigator or designee will pull the appropr iate test articles fr om the study supply. 
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed outside the clinical site) or not, must be recorded on the Test Article Accountability Log in the “Dispensed” section. 
5.2. Masking 
To reduce the possibility of bias, this will be a double-masked trial. Subjects will not be aware of the identity of the assigned lenses. The identity of the study lenses will be masked by having the blister packs labeled with the study numbe r, lot number, sphere power, cylinder power, 
axis, expiration date and ra ndomization code. While clini cal trial personnel (including 
investigators, site technician s, data management, the study biostatistician and clinical 
CR-6482, v 2.0  
Page 21 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
operations personnel) will be aware of the parameters of the test and control lenses (material, 
design, etc. including brand and type of the cont rol lenses), every atte mpt will be made to 
ensure they are not made aware of the corresponding randomization codes for the test and 
control articles. Only the unmasked Biostatistician generating the randomization scheme (lens fitting schedule) will have access to the decode information that allows matching of the 
randomization codes to the investigational designs. The medical monitor will also have access to the decode information in case breaking the mask is necessary for the urgent medical treatment of a subject.  
5.3. Procedures for Maintaining and Breaking the Masking 
Under normal circumstances, the mask should not be broken until all subj ects have completed 
the study and the database is finalized. Otherwise, the mask shoul d be broken only if specific 
emergency treatment/course of ac tion would be dictated by knowing the treatment status of the 
subject. In such cases, the Investigator may, in  an emergency, contact the medical monitor. In 
the event the mask is broken, the Sponsor must be informed as soon as possible. The date, 
time, and reason for the unmasking must be documented in the subject record. The Investigator is also advised not to reveal the study treatment  assignment to the clinical site or Sponsor 
personnel.   Subjects who have had their tr eatment assignment unmasked are expected to return for all 
remaining scheduled evaluations. Subjects who are discontinued may be replaced at the discretion of the study sponsor.   
6. STUDY INTERVENTION 
6.1. Identity of Test Articles  
The following contact lenses will be used in this study: 
 
CR-6482, v 2.0  
Page 22 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
8. SUBJECTS COMPLETION/WITHDRAWAL  
8.1. Completion Criteria 
Subjects are considered to have  completed the study if they:  
x provided informed consent. 
x they are eligible. 
x have not withdrawn/discontinued from th e study for any reason described in 
section 8.2. 
x completed all visits through the final visit (visit 4). If all visits were completed but an 
additional visit is considered necessary for subject care, follow the requirements for unscheduled visits in section 7.3. 
8.2. Withdrawal/Discontinuation from the Study 
A subject will be withdrawn from the study for any of the following reasons: 
x Subject withdrawal of consent. 
x Subject not compliant to protocol. 
x Subject lost to follow-up. 
x Subject no longer meets eligibility criteri a (e.g. the subject becomes pregnant). 
x Subject develops significant or serious adverse events necessitating discontinuation of 
study lens wear . 
x Subjects who have experienced a Corneal Infiltrative Event (CIE). 
x Investigator’s clinical judgment regarding the subject safety reasons (that it is in the best interest of the subject to stop treatment). 
x Subject misses any study visits . 
x Subject not compliant with study lens wear schedule.  
x Subject not successfully dispensed due to lack of efficacy and safety including poor 
vision, poor comfort or unacceptable fit.  
For discontinued subjects, the Investigator will: 
x Complete the current visit (scheduled or unscheduled). 
x Complete the Final Evaluation, indicating th e reason that the subject was discontinued 
from the study. 
x Record the spherocylindrical refraction with best corrected distance visual acuity. 
x Collect used test article(s) (worn or brought to the visit) from the subject and discard 
them, unless otherwise stated in section 7.2. 
x Collect all unused test article(s) from the subject. 
x Make arrangements for subject care, if needed, due to their study participation 
 
Additional subjects may be enrolled if a subj ect discontinues from the study prematurely.  
 In cases where a subject is lost to follow-up, ever y possible effort must be made to contact the 
subject and determine the reason for discontinua tion/withdrawal. The measures taken to follow 
CR-6482, v 2.0  
Page 41 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 
JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The study can be terminated by the Principal Investig ator at the individual clinical site due to 
specific clinical observations, if in their opinion, after a discussion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.  JJVC (and the IEC/IRB and  DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event presents an unr easonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible. 
 Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulatory Authority as  required by local regulatory requirements. 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS 
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness or performance of test articles after they have been released for clinical trial use.    Potential complaints may come from a variety of sources including but not limited to subjects, clinical research associates (CRA), clinical operations managers (COM), medical monitors, and site personnel, etc. The following are not considered product quality complaints: 
x Subject satisfaction inquiries reported via “Subjective Questionnaires” and “Patient 
Reported Outcomes (PRO).” 
x Clinical test articles that are stored improperly or damaged after receipt at the 
investigational site. 
x Lens replacements that occur due to drops/fall-outs. 
x Damage deemed by clinicians or clinical staff to be caused by handling by the user, 
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where there is no deficiency alleged by the subject. 
 Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be 
recorded in the EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use is not configured to send automatic notificati ons or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.   
 Upon receipt of the EDC notification, the COM/ CRA will contact the study site to collect 
additional information which will include:  
x Date the complaint was received/recorde d in the EDC System (Date of Sponsor 
Awareness). 
x Who received the complaint. 
x Study number. 
CR-6482, v 2.0  
Page 45 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
x Clinical site information (contact name, site ID, telephone number). 
x Lot number(s). 
x Unique Subject Identifier(s). 
x Indication of who first observed co mplaint (site personnel or subject). 
x OD/OS indication, along with whet her the lens was inserted. 
x Any related AE number if applicable. 
x Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.). 
x Eye Care Provider objective (slit lamp) findings if applicable. 
x Confirmation of product availa bility for return (and tracking information, if available), 
or rationale if product is not available for return  
 
 
Once a complaint is received, it will be assessed by the COM, CRA, or trained site personnel to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or traine d site personnel will follo w section 13 of this 
protocol. If the AE/SAE was potentially the result of a product quality related deficiency, these procedures also applies and will be executed in parallel.    In some cases, a PQC form may be generated in EDC by the site in error. In this event, the PQC forms will be marked “Intentionally Left Bla nk” or “ILB”.  Justification for ILB must be 
documented. 
13. ADVERSE EVENTS 
13.1. Definitions and Classifications 
Adverse Event (AE) – An AE is “any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investig ational medical device.”  
Note : This definition includes events related to  the investigational medical device or the 
comparator, and to the procedures involved. Fo r users or other persons, this definition is 
restricted to events related to investigational medical devices.1 
 
An AE includes any condition (including a pre-existing condition) that: 
1. Was not present prior to the study, but app eared or reappeared following initiation of 
the study. 
2. Was present prior to the study but worsened  during the study. This would include any 
condition resulting from concomitant illnesses, reactions to concomitant medications, or progression of disease states. 
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immedi ately upon learning of the event. 
 Serious Adverse Event (SAE) – An SAE is any adverse event that led to any of the following: 
CR-6482, v 2.0  
Page 46 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
x Death 
x Serious deterioration in the health of the subject that resulted in any of the following: 
x Life-threatening illness or injury 
x Permanent or persistent impairment of a body structure or a body function 
x Hospitalization or prolongation of patient hospitalization 
x Medical or surgical intervention to prev ent life-threatening illness or injury or 
permanent impairment to a body structure or a body function. 
x Chronic disease 
x Foetal distress, foetal death or a congenital physical or mental impairment of birth 
defect. 
 
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to: 
x Microbial Keratitis (MK) 
x Iritis (including cells in the anterior chamber) 
x Permanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines or greater 
x Central Corneal Opacity 
x Central Corneal Neovascularization 
x Uveitis 
x Endophthalmitis 
x Hypopyon 
x Hyphemia 
x Penetration of Bo wman’s Membrane 
x Persistent Epithelial Defect 
x Limbal cell Damage leading to Conjunctivalization 
 Significant Adverse Events  – are defined as events that are symptomatic and warrant 
discontinuation (temporary or perman ent) of the contact lens wear 
 Diagnoses and conditions that are considered Ocular Significant Adverse Events include, but 
not limited to the following: 
x Contact Lens Induced Pe ripheral Ulcer (CLPU) 
x Significant Infiltrative Events (SIE) 
x Superior Epithelial Ar cuate Lesions (SEALs) 
x Any Temporary Loss of > 2 Lines of BSCVA 
x Other grade 3 or higher corneal findi ngs, such as abrasions or edema 
x Non-contact lens related corneal events - e.g. 
 Epidemic Kera toconjunctivitis (EKC) 
x Asymptomatic Corneal Scar 
x Any corneal event which necessitates te mporary lens discontinuation > 2 weeks 
 Non-Significant Adverse Events  – are defined as those events that are usually asymptomatic 
and usually do not warrant discon tinuation of contact lens wear but may cause a reduction in 
CR-6482, v 2.0  
Page 47 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
wear time.  However, the Investigator may choos e to prescribe treatment as a precautionary 
measure.   
 Diagnoses and conditions that are considered Ocular Non-Significant Adverse Events include, 
but not limited to the following: 
x Non-significant Infiltrative Event (NSIE) 
x Contact Lens Papillary Conjunctivitis (CLPC) 
x Superficial Punctate Keratitis (SPK) 
x Conjunctivitis: Bacterial, Viral, Allergic 
x Blepharitis 
x Meibomianitis 
x Contact Dermatitis 
x Localized Allergic Reactions 
x Any corneal event not explicitly defined as serious or significant adverse event, which necessitates temporary len VGLVFRQWLQXDWLRQZHHNV  
 
Adverse Device Effect (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device.” 
NOTE 1: This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantati on, installation, or opera tion, or any malfunction 
of the investigational medical device.  
NOTE 2: This definition includes any event resulting from use error or from intentional 
misuse of the investiga tional medical device.1 
 Unanticipated Adverse Device Effect (UADE) – A UADE is any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated with, the test 
article, if that effect, problem,  or death was not previously id entified in nature , severity, or 
degree of incidence in the investigational plan, Investigator’s Brochure or protocol, or any other unanticipated serious problem associated with the test article that relates to the rights, safety and welfare of subjects. 
13.2. Assessing Adverse Events 
In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are categorized correctly. Elements of categorization will include: 
x Seriousness/Classifications (s ee definition in section 13.1). 
x Causality or Relatedness – i.e. the relationship between the test article , study treatment 
or study procedures and the adverse even t (not related, unlikely related, possibly 
related, or related - see definition in section 13.2.1). 
x Adverse Event Severity – Adverse event seve rity is used to assess the degree of 
intensity of the adverse event (mild, m oderate, or severe - see definition in 
section 13.2.2). 
x Outcome – not recovered or not resolve d, recovering or resolving, recovered or 
resolved with sequelae, recovered or reso lved, death related to adverse event, or 
unknown. 
CR-6482, v 2.0  
Page 48 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
x Actions Taken – none, temporar ily discontinued, permanently  discontinued, or other. 
13.2.1. Causality Assessment 
Causality Assessment – A determination of the relationshi p between an adverse event and the 
test article. The test article relationship for each adverse event should be determined by the 
investigator using these explanations: 
x Not Related- An adverse event that is not re lated to the use of the test article, study 
treatment or study procedures. 
x Unlikely Related – An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatme nt, concomitant disease(s), or the relationship of time 
suggests that a causal relationship is not likely. 
x Possibly Related – An adverse event that might be due to the use of the test article, or 
to the study treatment or study procedures. An alternative explanation, e.g. concomitant treatment, concomitant disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship cannot be excluded. 
x Related – An adverse event that is listed as a possible adverse effect (device) or adverse reaction (drug) and cannot be reasonably e xplained by an alternative explanation, e.g. 
concomitant treatment of concomitant disease(s). The relationship in time is very suggestive, e.g. it is confirmed by de-challenge and re-challenge. 
13.2.2. Severity Assessment 
Severity Assessment – A qualitative assessment of the degree of intensity of an adverse event 
as determined by the Investigator or reported to him/her by the subject. The assessment of severity is made irrespective of  test article, study tr eatment or study procedure relationship or 
seriousness of the event and should be eval uated according to the following scale: 
x Mild – Event is noticeable to the subject but is easily tolerated and does not interfere with the subject’s daily activities. 
x Moderate – Event is bothersome, possibl e requiring additional therapy, and may 
interfere with the subject’s daily activities. 
x Severe – Event is intolerabl e, necessitates additional ther apy or alterati on of therapy 
and interferes with the subject’s daily activities. 
13.3. Documentation and Follow-Up of Adverse Events 
The recording and documenting of adverse even ts (ocular and non-ocular) begin when the 
subjects are exposed to the test article, study tr eatment or study procedure.  Adverse events 
reported before the use of test  article, start of st udy treatment, or study procedures will be 
recorded as medical history. However, if the c ondition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untoward medical events reported after the subject’s exit from the study will be recorded as adverse ev ents at the discretion of the Investigator. 
 Upon finding an adverse event, the Principal In vestigator will document the condition in the 
subject record and in the eCRFs and complete the Adverse Event eCRF.    
CR-6482, v 2.0  
Page 49 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
Complete descriptions of all adverse events must be available in the subject record. All 
Adverse Events including local and systemic re actions not meeting the criteria for “serious 
adverse events” shall be captured on the appropriate case report form or electronic data system. All adverse events occurring while the subject  is enrolled in the study must be documented 
appropriately regardle ss of relationship.   
 It is the Investigator’s responsibility to maintain documentation of each reported adverse event. All adverse events will be followed in accordance with applicable licensing requirements. Such 
documentation will include the following: 
x Adverse event (diagnosis not symptom). 
x Drawings or photographs (where appropri ate) that detail the finding (e.g., size, 
location, and depth, etc.). 
x Date the clinical site was notified. 
x Date and time of onset. 
x Date and time of resolution. 
x Adverse event classification, se verity, and relationship to te st articles, as applicable. 
x Treatment regimen instituted (where appropriate), including concomitant medications prescribed, in accordance with applicable licensing requirements. 
x Any referral to another hea lth care provider if needed. 
x Outcome, ocular damage (if any). 
x Likely etiology. 
x Best corrected visual acuity at the discovery of the ev ent and upon conclusion of the 
event, if the AE is related to the visual system. 
 Upon discovery of an AE that is deemed ‘possibl y related’ or ‘related’ to the test article or 
study procedures (whether related to the visual system or not), an  AE review form  
must be completed. Additiona l dated and initialed entries should be made at follow-up 
evaluations. Separate forms must be completed for each eye if the AE is bilateral.  
 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature. If cultures are collected, the date of culture collection and laboratory utilized will be recorded.   Changes in the severity of an AE shall be documented to allo w an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as intermittent require documentation of the onset and duration of each episode. Changes in the assessment of relationship to the Test Ar ticle shall also be clearly documented. 
 Subjects who present with an adverse event sh all be followed by the Investigator, within 
licensure, until all signs and symptoms have retu rned to pre-treatment status, stabilized, or 
been satisfactorily resolved. If further treatme nt beyond licensure is required, the patient will 
be referred to the appropriate health care provider. The Investigator will use his/her clinical judgment as to whether a subject reporting with an adverse event will continue in the study. If 
CR-6482, v 2.0  
Page 50 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
a subject is discontinued from the study, it will be  the responsibility of the Investigator to 
record the reason for discontinuation. The Inves tigator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse 
events related to the test artic le, study treatment or study procedur es, as of the final study visit 
date, should be followed to resolu tion of the adverse event or un til referral to an appropriate 
health care provider, as recommended by the Investigator. Non-ocular adverse events that are not related to the test artic le, study treatment, or study proc edures may be recorded as 
“ongoing” without further follow-up. 
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by e-mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant 
adverse events, and 2 days from discovery for any non-significant adverse event. In addition, 
a written report will be submitted by the Principal Investigator to the IEC/IRB according to 
their requirements (section 13.4.2). The report w ill comment whether the adverse event was 
considered to be related to the test ar ticle, study treatment or study procedures. 
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events 
The Investigator will inform the sponsor of a ll serious/significant adve rse events occurring 
during the study period as soon as possible by e- mail or telephone, but no  later than 24 hours 
following discovery of the event. The Invest igator is obligated to pursue and obtain 
information requested by the Sponsor in addition to that information reported on the eCRF. All 
subjects experiencing a serious/s ignificant adverse event must be followed up and all outcomes 
must be reported.  When medically necessary, the Investigator ma y break the randomizati on code to determine 
the identity of the treatment that the subject received. The Sponsor and study monitor should be notified prior to unmas king the test articles. 
 In the event of a serious/significant adverse event, the Investigator must: 
x Notify the Sponsor immediately. 
x Obtain and maintain in the subject’s records all pertinent medical information and medical judgment for colleague s who assisted in the treatment and follow-up of the 
subject. 
x Provide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test article. 
x Notify the IEC/IRB as required by the IE C/IRB reporting procedure according to 
national regulations. 
 
Unanticipated (Serious) Adverse Device Effect (UADE) In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
CR-6482, v 2.0  
Page 51 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
than 24 hours after the Investigator first learns of  the effect. This report is in addition to the 
immediate notificati on mentioned above. 
 
The Sponsor must conduct an evaluation of the UADE and must report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within 10 working days after 
the Sponsor first receives notification of the effect. 
 Non-Serious Adverse Events All non-serious adverse events, including non-seri ous adverse device effects, will be reported 
to the sponsor by the Investigator no later than 2 days from discovery. 
13.4.2. Reporting Adverse Events to the Respon sible IEC/IRB and Health Authorities 
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set forth 
by their Approving IEC/IRB. Each clinical site wi ll refer to and follow any guidelines set forth 
by their local governing Health Authorities. 
 The Sponsor will report applicable Adverse Events  to the local health authorities according to 
the written guidelines, including reporting timelines.  
13.5. Event of Special Interest 
None. 
13.6. Reporting of Pregnancy 
Subjects reporting pregnancy (by self-report) during the study will be discontinued after the event is recorded as an Adverse Event. Once  discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact lens or  solution related studies for safety concerns, but due to 
general concerns relating to pre gnancy and contact lens use. Sp ecifically, pregnant women are 
discontinued due to fluctuations in refractive error and/or visual  acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus. 
14. STATISTICAL METHODS 
14.1. General Considerations 
Statistical Analysis will be undertaken by the sponsor or under the authority of the sponsor. A 
general description of the statistical methods to be  implemented in this c linical trial is outlined 
below.   
 All data summaries and statistical analyses will be performed using the SAS software Version 9.4 or higher (SAS Institute, Cary, NC).  Throughout  the analysis of data, the results for each 
subject/eye will be used when available for summarization and statistical analysis.  
 
CR-6482, v 2.0  
Page 52 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
Summary tables (descriptive statistics and/or frequency tables) will be provided for all baseline 
variables, efficacy variables and safety variab les as appropriate. Con tinuous variables will be 
summarized with descriptive statistics (n, mean, standard deviation (SD), median, minimum and maximum). Frequency count and percentage of subjects or eyes within each category will be provided for categorical data. 
14.2. Sample Size Justification 
Approximately 66 subjects will be  enrolled in this study to attain a minimum of 60 completed 
subjects. All endpoints will be su mmarized using descriptive statis tics describe in section 14.1; 
no hypothesis is planned to be te sted. Sample size is selected to limit the exposure to the new 
hydration process, and to evaluate the clinical  performance of AO1DfA produced with PG vs. 
IPA hydration.  
14.3. Analysis Populations 
Safety Population: 
All subjects who are administered any test ar ticle excluding subjects who drop out prior to 
administering any test article. At least one observation should be recorded. 
 Per-Protocol Population:  All subjects who successfully complete all visits and do not substantially deviate from the protocol as determined by th e trial cohort review committee pr ior to database hard lock. 
Justification for the exclusion of subjects with protocol de viations from the Per-Protocol 
Population set will be docume nted in a memo to file. 
 
Intent-to-Treat (ITT) Population: All randomized subjects regardless of actual tr eatment and subsequent withdrawal from the 
study or deviation from the protocol. At least one observation should be recorded. 
14.4. Level of Statisti cal Significance 
No inferential statistics ar e planned to be performed in this st udy; hence, the level of statistical 
significance is not a concern.  If any post-hoc st atistical analysis after reviewing data is 
conducted, a type I error rate of 5% w ill be used for exploratory purposes. 
14.5. Primary Analysis 
Descriptive summary of the pr imary endpoint by treatment arm will be provided for safety 
population. 
x Incidence of grade 3 or higher biomicrosc opy findings using the FDA grading scale 
following a 7(±2) day wear period  
14.6. Secondary Analysis 
Not applicable.   
CR-6482, v 2.0  
Page 53 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
14.7. Other Exploratory Analysis 
Descriptive summary of the following efficacy  endpoints by treatment arm  will be provided 
for both intent-to-treat and per-protocol population. 
x Subjective comfort, vision and handling at fitting and following a 7(±2) day wear 
period using the CLUE questionnaire 
x High-luminance, high-contrast (HLHC) visu al acuity in logMAR measured using 
ETDRS charts at follow-up 
x Lens orientation at 1 minute and 3 minutes following insertion at fitting 
x Mean and standard deviation of settled lens orientation calculated from repeated measures of settled lens orientation at fitting and follow-up visits  
   
14.8. Interim Analysis 
Not applicable.   
14.9. Procedure for Handling Missing Data and Drop-Outs 
Missing or spurious values will not be imputed. The count of mi ssing values will be included 
in the summary tables and listings.  
14.10. Procedure for Reporting Deviat ions from Statistical Plan 
The analysis will be conducted according to that specified in above sections. There are no known reasons for which it is planned to deviate fr om these analysis methods. If for any reason 
a change is made, the change will be documented in the study re port along with a justification 
for the change. 
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING 
15.1. Electronic Case Report Form/Data Collection 
The data for this study will be captured on electronic case report forms (eCRFs) using the 
BioClinica EDC system. An authorized data or iginator will enter study data into the eCRFs 
using the EDC system. Data collected on equipment that is not captured in EDC will be formatted to the specification of the JJVC databa se manager and sent to JJVC for analysis.  
 No external data sources will be included in this study.  
 The clinical data will be recorded on dedicated eCRFs specifically designed to match the study procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once completed, the eCRFs will be reviewed for accuracy and completeness and signed by the Investigator. The sponsor or sponsor’s representatives will be authorized to gain access to the subject recordation for the purposes of  monitoring and auditing the study.  
 
CR-6482, v 2.0  
Page 54 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and 
complete data collection. Data w ill be transmitted from the clini cal site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with Individual Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of the study data. The IPP must be retained in the st udy files as a certified c opy of the source data 
for the study.   The content and structure of the eCRFs are compliant with ISO14155:2020.
1 
15.2. Subject Record 
At a minimum, subject record should be available for the following:  
x subject identification 
x eligibility 
x study identification 
x study discussion 
x provision of and date of informed consent 
x visit dates 
x results of safety and efficacy para meters as required by the protocol 
x a record of all adverse events 
x follow-up of adverse events 
x medical history and concomitant medication 
x test article receipt/dispensing/return records 
x date of study completion 
x reason for early discontinuation of test article or withdrawal from the study, if applicable  
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of  entry is considered to be the source record. 
 Adverse event notes must be reviewed and initialed by the Investigator. 
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by the Sponsor. 
16. DATA MANAGEMENT 
16.1. Access to Source Data/Document 
The Investigator/Institution will permit trial-rela ted monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source data/documents. Should the 
clinical site be contacted for an audit by an IEC/IRB or regulatory authority, JJVC must be 
contacted and notified in  writing within 24 hours. 
CR-6482, v 2.0  
Page 55 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
16.2. Confidentiality of Information 
Information concerning the inves tigational product and pa tent application pro cesses, scientific 
data or other pertinent inform ation is confidential and rema ins the property of JJVC. The 
Investigator may use this information for the purposes of the study only. It is understood by 
the Investigator that JJVC will use information developed in this clinical study in connection 
with the development of the investigational product a nd therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands  that he/she has an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor. 
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of data, include the selection of 
qualified investigators and appropriate clinical sites and revi ew of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site  personnel are familiar with the pr otocol and all study-specific 
procedures and have appropriate  knowledge of the study article. 
 Training on case report form comp letion will be provided to clini cal site personnel before the 
start of the study. The Sponsor will review case  report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be resolved with the Investigator or designee, as appropriate.  Quality Assurance representatives from JJVC may visit clinical sites to review data produced during the study and to access compliance with applicable regulations pertaining to the conduct of clinical trials. The clinical sites will provide direct access to study-related source data/documents and reports for the purpose of monitoring and auditing by JJVC and for inspection by local and regulatory authorities. 
16.4. Data Monitoring Committee (DMC) 
Not applicable. 
17. CLINICAL MONITORING 
The study monitors will maintain close contact  with the Principal Investigator and the 
Investigator’s designated clinical site personnel. The monitor’s resp onsibilities will include: 
x Ensuring that the investigation is being conducted according to the protocol, any 
subsequent versions, and regulat ory requirements are maintained. 
x Ensuring the rights and wellbei ng of subjects are protected. 
x Ensuring adequate resources, including fac ilities, laboratories, equipment, and 
qualified clinical site personnel. 
CR-6482, v 2.0  
Page 56 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
x Ensuring that protocol deviations are doc umented with corrective action plans, as 
applicable. 
x Ensuring that the clinical site has sufficient test article and supplies. 
x Clarifying questions regarding the study. 
x Resolving study issues or problems that may arise. 
x Reviewing of study records and source documentation verification in accordance with 
the monitoring plan. 
18. ETHICAL AND REGULATORY ASPECTS 
18.1. Study-Specific Design Considerations 
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects  will be given any new information that may affect their decision to continue 
participation. Subjects will be told that their consent to participate in the study is voluntary and 
may be withdrawn at any time with  no reason given and without pena lty or loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if the fully able to understand the risks, benefits, and potential adve rse events of the study and provide their 
consent voluntarily. 
18.2. Investigator Responsibility 
The Principal Investigator is responsible for en suring that the clinical study is performed in 
accordance with the signed agreement, the investigational plan, section 4 of the ICH E6(R2) guidelines on Good Clinical Practice (GCP),
2 and applicable regulatory requirements. GCP is 
an international ethical and sc ientific quality standard for designing, conducting, recording, 
and reporting studies that involve the particip ation of human subjects. Compliance with this 
standard provides public assurance that the right s, safety, and well-bei ng of study subjects are 
protected, consistent with the principl es of the Declaration of Helsinki 64th WMA General 
Assembly 20133 and that the clinical study data are credible. The Investigator must maintain 
clinical study files in accordance with section 8 of the ICH E6(R2) guidelines on Good Clinical Practice (GCP),
2 and applicable regul atory requirements. 
18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB) 
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copies of  the following documents (where applicable): 
x Final protocol. 
x Sponsor-approved informed consent form (a nd any other written materials to be 
provided to the subjects) 
x Investigator’s Brochure (o r equivalent information). 
x Sponsor-approved subject r ecruitment materials. 
x Information on compensation for study-relate d injuries or payment to subjects for 
participation in the study. 
CR-6482, v 2.0  
Page 57 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
x Investigator’s curriculum vitae, clinical li censes, or equivalent information (unless not 
required, as documented by IEC/IRB). 
x Information regarding funding, name of th e Sponsor, institutiona l affiliations, other 
potential conflicts of interest, and incentives for subjects. 
x Any other documents that the IEC/IRB requests to fulfill its obligation. 
 
This study will be undertaken only after IEC/IRB has given full approval of  the final protocol, 
the informed consent form, applicable recruiting materials, and subject compensation programs, and the Sponsor has received a copy of  this approval. This approval letter must be 
dated and must clearly identify the documents being approved. 
 During the study, the Investigator (or Sponsor  when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate: 
x Protocol revisions 
x Revision(s) to informed consent form and any other written materials to be provided to subjects 
x If applicable, new or revise d subject recruitment materi als approved by the Sponsor 
x Revisions to compensation for study-relate d injuries or payment to subjects for 
participation in the study 
x Investigator’s Brochure revisions  
x Summaries of the status of the study (at leas t annually or at intervals stipulated in 
guidelines of the IEC/IRB) 
x Reports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRB’s requirements 
x New information that may adversely affect th e safety of the subjects or the conduct of 
the study 
x Major protocol deviations as required by the IEC/IRB 
x Report of deaths of subjects under the Investigator's care 
x Notification if a new Investigator is res ponsible for the study at the clinical site 
x Any other requirements of the IEC/IRB 
 For protocol revisions that incr ease subject risk, the revisions a nd applicable informed consent 
form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s).  At least once a year, the IEC/IRB will review and reapprove this clinical study. This request should be documented in writing.  At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB about the study completion. Documentation of this no tification must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable. 
CR-6482, v 2.0  
Page 58 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
18.4. Informed Consent 
Each subject or their representative, must give written consent according to local requirements 
after the nature of the study has been fully explained. The consent form must be signed before performance of any study-related activity. The cons ent form that is used must be approved by 
both the Sponsor and by the reviewing IEC/IRB. Th e informed consent is in accordance with 
principles that originated in the Declaration of Helsinki,
3 current ICH GCP2 and ISO 
14155:20201 guidelines, applicable regulatory requirements, and Sponsor Policy. 
 Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discom fort it may entail. Subjects will be informed 
that their participation is voluntary and that they may withdraw consent to participate at any time.  
 
The subject will be given sufficient time to read  the informed consent form and the opportunity 
to ask questions. After this explanation and before entry into the study, consent should be appropriately recorded by means of the subj ect's dated signature. After having obtained the 
consent, a copy of the informed consen t form must be given to the subject. 
18.5. Privacy of Personal Data 
The collection, processing and disclosure of pers onal data and medical information related to 
the Study Subject, and personal data  related to Principal Investig ator and any clinical site 
personnel (e.g., name, clinic addr ess and phone number, curriculum vitae) is subject to 
compliance with the United States
7 and other applicable personal data protection and security 
laws and regulations. Appropriate measures will be employed to safeguard these data, to maintain the confidentiality of the person’s related health and medical information, to properly 
inform the concerned persons about the collec tion and processing of th eir personal data, to 
grant them reasonable access to their personal  data and to prevent access by unauthorized 
persons.  All information obtained during the course of the investigation will be regarded as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by Investigators, monitors, Sponsor’s personnel and IEC/IRB. No data will be disclose d to any third party 
without the express permission of the subject  concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulat ory organizations in the context of their 
investigation related activities that, as part of the investigation will have access to the CRFs and subject records.  The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to investigate the efficacy, safety, quality, and utility of the investigational product( s) used in this study. 
 These data must be collected and processed with adequate precautions to ensure confidentiality and compliance with applicable data pr ivacy protection laws and regulations. 
CR-6482, v 2.0  
Page 59 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
The Sponsor ensures that the personal data will be: 
x processed fairly and lawfully. 
x collected for specified, explicit, and legitimate purposes and not further processed in a 
way incompatible with these purposes. 
x adequate, relevant, and not excessive in relation to said purposes. 
x accurate and, where necessary, kept current. 
 Explicit consent for the processing of personal data will be obtained from the participating subject before collection of data . Such consent should also addre ss the transfer of the data to 
other entities and to other countries.  The subject has the right to request through the Investigator access to hi s personal data and the 
right to request rectification of  any data that are not correct or complete. Reasonable steps 
should be taken to respond to such  a request, taking into considera tion the nature of the request, 
the conditions of the study, and the applicable laws and regulations. 
 Appropriate technical and orga nizational measures to protec t the personal data against 
unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor pe rsonnel whose responsibilities require access to 
personal data agree to keep the id entity of study subjects confidential. 
19. STUDY RECORD RETENTION 
In compliance with the ICH GCP guidelines,
2 the Investigator/Institution will maintain all 
CRFs and all subject records that support the data  collected from each subject, as well as all 
study documents as specified in ICH GCP2 and all study documents as specified by the 
applicable regulatory requirement(s). The Investigator/Institution will take measures to prevent accidental or premature destruction of these documents.  Essential documents must be retained until at least two (2) years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least two (2) years have elapsed since the formal discontinuation of clin ical development of the i nvestigational product. These 
documents will be retained for a longer peri od if required by the applicable regulatory 
requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained. 
 If the responsible Investigator retires, relocat es, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will accept the responsibility. The Sponsor must be no tified in writing of the name and address of 
the new custodian. Under no circumstance shall the Investigator relocate or dispose of any study documents before having obtaine d written approval from the Sponsor. 
 
CR-6482, v 2.0  
Page 60 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
If it becomes necessary for the Sponsor or the ap propriate regulatory auth ority to review any 
documentation relating to this study, the Investig ator must permit access to such reports.  
If the Investigator has a question regarding rete ntion of study records, he/she should contact 
JJVC.  
20. FINANCIAL CONSIDERATIONS 
Remuneration for study services and expenses will be set forth in de tail in the Clinical Research 
Agreement. The Research Agreement will be signed by the Principal Investigator and a JJVC 
management representativ e prior to study initiation. 
 JJVC reserves the right to withhold remuneration fo r costs associated with protocol violations 
such as: 
x Continuing an ineligible subject in the study. 
x Scheduling a study visit outside the subject’s acceptable visit range. 
 
JJVC reserves the right to withhold final rem uneration until all study related activ ities have 
been completed, such as: 
x Query resolution. 
x Case Report Form signature. 
x Completion of any follow-up action items. 
21. PUBLICATION 
There is no plan to externally publish the results of this investigation. 
22. REFERENCES 
1. ISO 14155:2020: Clinical Investigation of Medical Devices for Human Subjects — 
Good Clinical Practice. Available at: https://www.iso.org/standard/71690.html 
2. International Council for Harmonization Good Clinical Practice E6(R2) (ICH GCP). 
Available at: https://www.ich.or g/page/efficacy-guidelines 
3. Declaration of Helsinki - Ethical principles for Medical  Research Involving Human 
Subjects. Available at: https://www.wm a.net/policies-post/w ma-declaration-of-
helsinki-ethical-principles-for-medic al-research-involvi ng-human-subjects/  
4. United States (US) Code of Federa l Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collec tionCfr.action?collectionCode=CFR  
5. Straker B. Investigator’s Brochure: ACUVUE
® OASYS 1-Day for ASTIGMATISM 
Toric Soft Contact Lens Manufactured with Propylene Glycol Hydration.  2022.   
6. Hamada, W. Clinical Study Report  Three-way Cross-over 
Evaluation of Senofilcon-based Prototype C2 Acuvue® Oasys® for Astigmatism Toric 
Lens Design using an Alternative Manufacturing Process and Acuvue® Oasys® Brand 
for Astigmatism. May 29, 2014. 
CR-6482, v 2.0  
Page 61 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
7. Health Information Portability and Acc ountability Act (HIPAA). Available at: 
https://www.hhs.gov/hipaa/for-profe ssionals/privacy/index.html  
 
  
CR-6482, v 2.0  
Page 62 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
  
CR-6482, v 2.0  
Page 63 of 163JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1Clinical Study Protocol
CR-6482, v 2.0  
Page 64 of 163JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2Clinical Study Protocol
CR-6482, v 2.0  
Page 65 of 163JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3Clinical Study Protocol
CR-6482, v 2.0  
Page 66 of 163JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4Clinical Study Protocol
CR-6482, v 2.0  
Page 67 of 163JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5Clinical Study Protocol
CR-6482, v 2.0  
Page 68 of 163JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6Clinical Study Protocol
CR-6482, v 2.0  
Page 69 of 163JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7Clinical Study Protocol
CR-6482, v 2.0  
Page 70 of 163JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8Clinical Study Protocol
CR-6482, v 2.0  
Page 71 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
APPENDIX B: PATIENT INSTRUCTION GUIDE   The patient instruction guide (PIG) will be provided separately.  
CR-6482, v 2.0  
Page 72 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
  
CR-6482, v 2.0  
Page 73 of 163JJVC CONFIDENTIAL
DESCRIPTION
ACUVUE OASYS® Brand Contact Lenses 1-Day and ACUVUE OASYS® 
Brand Contact Lenses 1-Day for ASTIGMATISM are soft (hydrophilic) 
contact lenses made with HydraLuxe™ Technology. They are available as spherical or toric lenses respectively. 
These lenses are made of a silicone hydrogel material containing an internal 
wetting agent, visibility tint, and UV absorbing monomer and are tinted blue using Reactive Blue Dye #4 to make the lenses more visible for handling.
A benzotriazole UV absorbing monomer is used to block UV radiation. The 
transmittance characteristics for these lenses are less than 1% in the UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 316 nm to 380 nm 
for the entire power range.
Lens Properties:
The physical/optical properties of the lens are:
• Speciﬁ  c Gravity (calculated): 0.98 - 1.12
• Refractive Index: 1.42
• Light Transmission: 85% minimum• Surface Character: Hydrophilic• Water Content: 38%
• Oxygen Permeability:
VALUE METHOD
122 x 10
-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, non-
edge corrected)
103 x 10-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, edge corrected)
Lens Parameters:
• Diameter Range: 12.0 mm to 15.0 mm
• Center Thickness: varies with power
• Base Curve Range: 7.85 mm to 10.00 mm
• Spherical Power Range: -20.00D to +20.00D
• Cylinder Power Range: -0.25D to -10.00D
• Axis Range: 2.5° to 180°Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 76 of 163JJVC CONFIDENTIAL
AVAILABLE LENS PARAMETERS
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology are 
hemispherical shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.085 mm to 0.221 mm (varies with power)
Base Curve: 8.5 mm, 9.0 mm
Powers: -0.50D to -6.00D (in 0.25D increments)
-6.50D to -12.00D (in 0.50D increments)+0.50D to +6.00D (in 0.25D increments)+6.50D to +8.00D (in 0.50D increments)
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology for 
ASTIGMATISM  are hemitoric shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.075 mm to 0.172 mm (varies with power)
Base Curve: 8.5 mm
Powers: +0.00D to -6.00D (in 0.25D increments)
Cylinders: -0.75D, -1.25D, -1.75D, -2.25D*Axis: 10° to 180° in 10° increments
*-2.25D cylinder is availble in 10°, 20°, 70°, 80°, 90°, 100°, 110°, 
160°, 170°, 180° axes only.
+0.25D to +4.00D (in 0.25D increments)
-6.50D to -9.00D (in 0.50D increments)Cylinders: -0.75D, -1.25D, -1.75DAxis: 10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°, 
170°, 180°Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 77 of 163JJVC CONFIDENTIAL
TRANSMITTANCE CURVES
ACUVUE OASYS® 1-Day with HydraLuxe™ Technology  (senoﬁ  lcon A) 
Visibility Tinted with UV Blocker vs. 24 yr. old human cornea and 25 yr. old 
human crystalline lens. 
……. ACUVUE OASYS®  
1-Day with HydraLuxe™ Technology (senoﬁ  lcon A)*
_____ 24 YR. OLD HUMAN CORNEA
1
- - - - - 25 YR. OLD HUMAN CRYSTALLINE LENS
2
* The data was obtained from measurements taken through the central 3-5 mm portion for 
the thinnest marketed lens (-9.00D lens, 0.075 mm center thickness).
1Lerman, S., Radiant Energy and the Eye, MacMillan, New York, 1980, p. 58, ﬁ  gure 2-21
2Waxler, M., Hitchins, V.M., Optical Radiation and Visual Health, CRC Press, Boca Raton, Florida, 
1986, p. 19, ﬁ  gure 5 
WARNING: UV absorbing contact lenses are NOT substitutes for 
protective UV absorbing eyewear, such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. The patient should continue to use UV absorbing eyewear as directed.
ACTIONS
In its hydrated state, the contact lens, when placed on the cornea, acts as a refracting medium to focus light rays onto the retina.
The transmittance characteristics for these lenses are less than 1% in the 
UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 316 nm to 380 nm for the entire power range.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 78 of 163JJVC CONFIDENTIAL
NOTE:  Long-term exposure to UV radiation is one of the risk 
factors associated with cataracts.  Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities).  UV-Blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-Blocking contact lenses reduces the risk of developing cataracts or other eye disorders. The Eye Care Professional should be consulted for more information.
INDICATIONS (USES)
ACUVUE OASYS® Brand Contact Lenses 1-Day with HydraLuxe™ 
Technology are indicated for daily disposable wear for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who may have 1.00D or less of astigmatism.
ACUVUE OASYS® Brand Contact Lenses 1-Day with HydraLuxe™ Tech-
nology for ASTIGMATISM are indicated for daily disposable wear for the 
optical correction of refractive ametropia (myopia and hyperopia) in phakic 
or aphakic persons with non-diseased eyes who may have 0.50D to 3.00D of astigmatism.
These lenses contain a UV Blocker to help protect against transmission of 
harmful UV radiation to the cornea and into the eye.
CONTRAINDICATIONS (REASONS NOT TO USE) 
DO NOT USE these contact lenses when any of the following conditions exist:
• Acute or subacute inﬂ  ammation or infection of the anterior chamber 
of the eye.
• Any eye disease, injury or abnormality that affects the cornea, 
conjunctiva, or eyelids.
• Severe insufﬁ  ciency of lacrimal secretion (dry eye).Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 79 of 163JJVC CONFIDENTIAL
• Corneal hypoesthesia (reduced corneal sensitivity).
• Any systemic disease that may affect the eye or be exaggerated by 
wearing contact lenses.
• Allergic reactions of ocular surfaces or adnexa that may be induced 
or exaggerated by wearing contact lenses or use of contact lens 
solutions.
• Ocular irritation due to allergic reactions which may be caused by 
use of contact lens solutions (i.e., rewetting drops) that contain chemicals or preservatives (such as mercury, Thimerosal, etc.) to which some people may develop an allergic response.
• Any active corneal infection (bacterial, fungal, protozoal, or viral).
• If eyes become red or irritated.
WARNINGS
Patients should be advised of the following warnings pertaining to 
contact lens wear:
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP 
RAPIDLY AND LEAD TO LOSS OF VISION; IF THE PATIENT EXPE-RIENCES:
• Eye Discomfort,
• Excessive Tearing,• Vision Changes,• Loss of Vision,• Eye Redness,• Or Other Eye Problems, 
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY RE-
MOVE THE LENSES AND PROMPTLY CONTACT THE EYE CARE PROFESSIONAL.
• When prescribed for daily wear, patients should be instructed not 
to wear lenses while sleeping. Clinical studies have shown that 
the risk of serious adverse reactions is increased when lenses are worn overnight, and that the risk of ulcerative keratitis is greater for Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 80 of 163JJVC CONFIDENTIAL
extended wear contact lens users than for daily wear users.3
• Studies have shown that contact lens wearers who are smokers 
have a higher incidence of adverse reactions than nonsmokers.
• Problems with contact lenses or lens care products could result in 
serious injury to the eye. Patients should be cautioned that proper 
use and care of contact lenses and lens care products are essential for the safe use of these products.
• The overall risk of ulcerative keratitis may be reduced by carefully 
following directions for lens care.
3 New England Journal of Medicine, September 21, 1989; 321 (12), pp. 773-783
Speciﬁ  c Instructions for Use and Warnings:
• Water Activity
Instructions for Use
Do not expose contact lenses to water while wearing them.WARNING:
Water can harbor microorganisms that can lead to severe infection, vision loss or blindness. If lenses have been submersed in water when participating in water sports or swimming in pools, hot tubs, lakes, or oceans, the patient should be instructed to discard them and replace them with a new pair. The Eye Care Professional should be consulted for recommendations regarding wearing lenses during any activity involving water.
PRECAUTIONS
Special Precautions for Eye Care Professionals:
• Due to the small number of patients enrolled in clinical investiga-
tion of lenses, all refractive powers, design conﬁ  gurations, or lens parameters available in the lens material are not evaluated in signif-icant numbers. Consequently, when selecting an appropriate lens design and parameters, the Eye Care Professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, wettability, central and peripheral thickness, and optic zone diameter.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 81 of 163JJVC CONFIDENTIAL
• The potential impact of these factors on the patient’s ocular health 
should be carefully weighed against the patient’s need for refractive 
correction; therefore, the continuing ocular health of the patient and lens performance on the eye should be carefully monitored by the prescribing Eye Care Professional.
• Patients who wear these lenses to correct presbyopia using mono-
vision may not achieve the best corrected visual acuity for either far or near vision. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
• Fluorescein, a yellow dye, should not be used while the lenses are 
on the eyes. The lenses absorb this dye and become discolored. Whenever ﬂ  uorescein is used in eyes, the eyes should be ﬂ  ushed with a sterile saline solution that is recommended for in-eye use.
• Eye Care Professionals should instruct the patient to remove the 
lenses immediately if the eyes become red or irritated. 
Eye Care Professionals should carefully instruct patients about the following care regimen and safety precautions.
Handling Precautions:
• Before leaving the Eye Care Professional’s ofﬁ  ce, the patient should 
be able to promptly remove the lenses or should have someone 
else available who can remove the lenses for him or her. 
• DO NOT use if the sterile blister package is opened or damaged. 
• Always wash and rinse hands before handling lenses. Do not get 
cosmetics, lotions, soaps, creams, deodorants, or sprays in the 
eyes or on the lenses. It is best to put on lenses before putting on makeup. Water-based cosmetics are less likely to damage lenses than oil-based products. 
• DO NOT touch contact lenses with the ﬁ  ngers or hands if the 
hands are not free of foreign materials, as microscopic scratches of the lenses may occur, causing distorted vision and/or injury to the eye.
• Carefully follow the handling, insertion, removal, and wearing 
instructions in the “Patient Instruction Guide” for the prescribed Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 82 of 163JJVC CONFIDENTIAL
wearing schedule and those prescribed by the Eye Care 
Professional.
• Always handle lenses carefully and avoid dropping them.
• Never use tweezers or other tools to remove lenses from the lens 
container unless speciﬁ  cally indicated for that use. Slide the lens up 
the side of the bowl until it is free of the container. 
• Do not touch the lens with ﬁ  ngernails. 
Lens Wearing Precautions:
• If the lens sticks (stops moving) on the eye, follow the recom-
mended directions in “Care for a Sticking (Non-Moving) Lens." The lens should move freely on the eye for the continued health of the eye. If non-movement of the lens continues, the patient should be instructed to immediately consult his or her Eye Care Professional.
• Never wear lenses beyond the period recommended by the Eye 
Care Professional.
• The patient should be advised to never allow anyone else to wear 
their lenses. They have been prescribed to ﬁ  t their eyes and to correct their vision to the degree necessary. Sharing lenses greatly increases the chance of eye infections.
• If aerosol products, such as hair spray, are used while wearing 
lenses, exercise caution and keep eyes closed until the spray has settled.
• Avoid all harmful or irritating vapors and fumes while wearing 
lenses. 
• Always discard lenses worn as prescribed by the Eye Care 
Professional. 
Lens Care Precautions:  
• The patient should be informed that no cleaning or disinfection is 
needed when lenses are worn for daily disposable wear.  Patients should always dispose of lenses when removed and have spare lenses or spectacles available.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 83 of 163JJVC CONFIDENTIAL
Other Topics to Discuss with Patients:
• Always contact the Eye Care Professional before using any medi-
cine in the eyes. 
• Certain medications, such as antihistamines, decongestants, 
diuretics, muscle relaxants, tranquilizers, and those for motion 
sickness may cause dryness of the eye, increased lens awareness, or blurred vision. Should such conditions exist, proper remedial measures should be prescribed. Depending on the severity, this could include the use of lubricating drops that are indicated for use with soft contact lenses or the temporary discontinuance of contact lens wear while such medication is being used. 
• Oral contraceptive users could develop visual changes or changes 
in lens tolerance when using contact lenses. Patients should be cautioned accordingly. 
• As with any contact lens, follow-up visits are necessary to assure 
the continuing health of the patient’s eyes. The patient should be instructed as to a recommended follow-up schedule. 
Who Should Know That the Patient is Wearing Contact Lenses?
• Patients should inform all doctors (Health Care Professionals) about 
being a contact lens wearer. 
• Patients should always inform their employer of being a contact 
lens wearer. Some jobs may require use of eye protection equip-ment or may require that the patient not wear contact lenses. 
ADVERSE REACTIONS
The patient should be informed that the following problems may occur when wearing contact lenses:
• The eye may burn, sting, and/or itch.
• There may be less comfort than when the lens was ﬁ  rst placed on 
the eye.
• There may be a feeling of something in the eye (foreign body, 
scratched area).
• There may be the potential for some temporary impairment due to Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 84 of 163JJVC CONFIDENTIAL
peripheral inﬁ  ltrates, peripheral corneal ulcers, or corneal erosion. 
There may be the potential for other physiological observations, such as local or generalized edema, corneal neovascularization, corneal staining, injection, tarsal abnormalities, iritis, and conjuncti-vitis; some of which are clinically acceptable in low amounts.
• There may be excessive watering, unusual eye secretions, or 
redness of the eye.
• Poor visual acuity, blurred vision, rainbows, or halos around 
objects, photophobia, or dry eyes may also occur if the lenses are worn continuously or for too long a time.
The patient should be instructed to conduct a simple 3-part self-examina-tion at least once a day. They should ask themselves:
• How do the lenses feel on my eyes?
• How do my eyes look?• Have I noticed a change in my vision? 
If the patient reports any problems, he or she should be instructed to 
IMMEDIATELY REMOVE THE LENS. If the problem or discomfort stops, the patient should discard the lens and place a new fresh lens on the eye.
If after inserting the new lens, the problem continues, the patient should be 
directed to IMMEDIATELY REMOVE THE LENS AND CONTACT HIS OR HER EYE CARE PROFESSIONAL.
The patient should be instructed NOT to use a new lens as self-treatment 
for the problem.
The patient should be advised that when any of the above symptoms oc-
cur, a serious condition such as infection, corneal ulcer, neovascularization, or iritis may be present. He or she should be instructed to seek immediate professional identiﬁ  cation of the problem and prompt treatment to avoid serious eye damage.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 85 of 163JJVC CONFIDENTIAL
GENERAL FITTING GUIDELINES
A. Patient Selection
Patients selected to wear these lenses should be chosen based on: 
• Motivation to wear lenses 
• Ability to follow instructions regarding lens wear care
• General health 
• Ability to adequately handle and care for the lenses 
• Ability to understand the risk and beneﬁ  ts of lens wear
Patients who do not meet the above criteria should not be provided with 
contact lenses. 
B. Pre-ﬁ  tting Examination
Initial evaluation of the patient should begin with a thorough case history 
to determine if there are any contraindications to contact lens wear. During 
the case history, the patient’s visual needs and expectations should be 
determined as well as an assessment of their overall ocular, physical, and 
mental health. 
Preceding the initial selection of trial contact lenses, a comprehensive 
ocular evaluation should be performed that includes, but is not limited to, 
the measurement of distance and near visual acuity, distance and near 
refractive prescription (including determining the preferred reading distance 
for presbyopes), keratometry, and biomicroscopic evaluation. 
Based on this evaluation, if it is determined that the patient is eligible to 
wear these lenses, the Eye Care Professional should proceed to the lens 
ﬁ  tting instructions as outlined below. 
C. Initial Power Determination
A spectacle refraction should be performed to establish the patient’s 
baseline refractive status and to guide in the selection of the appropriate 
lens power. Remember to compensate for vertex distance if the refraction 
is greater than ±4.00D.
D. Base Curve Selection (Trial Lens Fitting)
The following trial lenses should be selected for patients regardless of kera-
tometry readings. However, corneal curvature measurements should be 
performed to establish the patient’s baseline ocular status. Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 86 of 163JJVC CONFIDENTIAL
• ACUVUE OASYS® 1-Day: 8.5 mm/14.3 mm
• ACUVUE OASYS® 1-Day for ASTIGMATISM: 8.5 mm/14.3 mm
The trial lens should be placed on each of the patient's eyes and evaluated 
after the patient has adjusted to the lenses.  
1. Criteria of a Properly Fit Lens 
A properly ﬁ  t lens will center and completely cover the cornea (i.e., no limbal exposure), have sufﬁ  cient movement to provide tear exchange under the contact lens with the blink, and be comfortable. The lens should move freely when manipulated digitally with the lower lid, and then return to its properly centered position when released.
2. Criteria of a Flat Fitting Lens 
A ﬂ  at ﬁ  tting lens may exhibit one or more of the following characteris-tics: decentration, incomplete corneal coverage (i.e., limbal exposure), excessive movement with the blink, and/or edge standoff. If the lens is judged to be ﬂ  at ﬁ  tting, it should not be dispensed to the patient.
3. Criteria of a Steep Fitting Lens 
A steep ﬁ  tting lens may exhibit one or more of the following charac-teristics: insufﬁ  cient movement with the blink, conjunctival indentation, and resistance when pushing the lens up digitally with the lower lid. If the lens is judged to be steep ﬁ  tting, it should not be dispensed to the patient.
If the initial trial base curve is judged to be ﬂ  at or steep ﬁ  tting, the alternate base curve, if available, should be trial ﬁ  t and evaluated after the patient has adjusted to the lens. The lens should move freely when manipulated digitally with the lower lid, and then return to a properly centered position when released. If resistance is encountered when pushing the lens up, the lens is ﬁ  tting tightly and should not be dispensed to the patient.
E. Final Lens Power (Spherical)
A spherical over-refraction should be performed to determine the ﬁ  nal lens power after the lens ﬁ  t is judged acceptable. The spherical over-refraction should be combined with the trial lens power to determine the ﬁ  nal lens prescription. The patient should experience good visual acuity with the correct lens power unless there is excessive residual astigmatism.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 87 of 163JJVC CONFIDENTIAL
Example 1
Diagnostic lens: -2.00DSpherical over-refraction: -0.25D
Final lens power: -2.25D
Example 2
Diagnostic lens: -2.00DSpherical over-refraction: +0.25D
Final lens power: -1.75D
If vision is acceptable, perform a slit lamp examination to assess adequate 
ﬁ  t (centration and movement). If the ﬁ  t is acceptable, dispense the lenses and instruct the patient to return in one week for reassessment (see dispensing and follow up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
TORIC FITTING GUIDELINES
Although most aspects of the ﬁ  tting procedure are identical for all types 
of soft contact lenses, including toric lenses, there are some additional steps and/or rules to follow to assure the proper ﬁ  t of toric lenses.
The only new steps you must follow in prescribing ACUVUE
 OASYS® 
1-Day for ASTIGMATISM are that you must determine the stability, 
repeatability, and drift angle of the lens axis so that you can prescribe the correct lens axis for the patient.
A. How to Determine Lens Cylinder and Axis Orientation 
1. Locate the Orientation Marks
To help determine the proper orientation of the toric lens, you’ll 
ﬁ  nd two primary marks approximately 1 mm from the lens edge representing the vertical position on opposite ends of the lens at 6 and 12 o’clock (Fig. 1). Because of the lens’ ballasting system, either mark can represent the vertical position – there is no “top” and “bottom” as in a prism-ballasted lens. You don’t need to view both marks to assess orientation; simply look for the 6 o’clock mark as you would with a prism-ballasted lens.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 88 of 163JJVC CONFIDENTIAL
Figure 1
You’ll need a slit lamp biomicroscope with a 1 to 2 mm 
parallelepiped beam to highlight the marks when the lens is ﬁ  tted to the eye. There are a number of techniques you can use to improve the visibility of the 6 o’clock mark. Using a parallelepiped beam and medium magniﬁ  cation (10x or 15x), slowly pan down the lens, looking just below the direct illumination at the retroilluminated area. Backlighting the mark this way should make it more visible. Sometimes manipulating the lower lid may be necessary to uncover the mark.
2. Observe Lens Rotation and Stability
Observe the position and stability of the “bottom” mark. It usually stabilizes at the 6 o’clock position. If it does, calculation of the lens power will be straightforward. The 6 o’clock position is not a “must”; however, the absolute requirement is that the axis position be stable and repeatable.
The mark may stabilize somewhat left or right (drift) of the vertical 
meridian and still enable you to ﬁ  t a toric lens for that eye, as long as the lens always returns to the same “drift axis” position after settling. The deviation can be compensated for in the ﬁ  nal prescription. Your objective is to ensure that whatever position the initial lens assumes near 6 o’clock, this position must be stable and repeatable. With full eye movement or heavy blink, you may see the marks swing away, but they must return quickly to the original stable position. If the lens does not return quickly, you may need to select a different lens.
3. Assessing Rotation
Imagine the eye as a clock dial and every hour represents a 30° interval. If the orientation mark of the initial lens stabilizes somewhat left or right of the vertical position, the ﬁ  nal lens will orient on the eye with the same deviation. You can use an axis reticule in the slit lamp or use a line-scribed lens in a spectacle trial frame to measure or estimate the “drift angle” of the cylinder axis.
To compensate for this “drift”, measure or estimate the “drift”, then 
add or subtract it from the refractive axis to determine the correct cylinder axis. Use the LARS (Left Add, Right Subtract) method to determine which direction to compensate.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 89 of 163JJVC CONFIDENTIAL
B. Final Lens Power 
When the diagnostic lens has its axis aligned in the same meridian 
as the patient’s refractive axis, a spherocylindrical over-refraction may be performed and visual acuity determined. However, in the case of crossed axes, such as when the diagnostic lens axis is different from the spectacle cylinder axis, it is not advisable to perform a full spherocylindrical over-refraction because of the difﬁ  culty in computing the resultant power. A spherical over-refraction without cylinder refraction may be performed. 
If the required cylinder correction falls between two available cylinder 
powers, it is recommended to prescribe the lower cylinder power lens. See below for instructions on how to determine the ﬁ  nal lens power.
1. For the Sphere
If sphere alone or combined sphere and cylinder Rx > ±4.00D, 
compensate for vertex distance. If sphere alone or combined sphere and cylinder Rx ≤ ±4.00D, vertex compensation is not necessary.
2. For the Cylinder
Adjust the axis by the drift angle using the LARS method. Choose a cylinder that is ≤ 0.50D from the refractive cylinder.
3. Case Examples
Example 1
Manifest (spectacle) refraction:
O.D. -2.50D / -1.25D x 180° 20/20O.S. -2.00D / -1.00D x 180° 20/20
Choose a diagnostic lens for each eye with axis 180°. Place 
the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient’s initial response to the lens. If the lens has not yet stabilized, recheck until stable.
Check the orientation of the axis mark. If the bottom axis mark 
is in the 6 o’clock position on both eyes, choose the appropriate cylinder as listed previously. If the lens has not yet stabilized, recheck until stable.
Here is the Rx Prescribed:
O.D. -2.50D / -1.25D x 180°O.S. -2.00D / -0.75D x 180°Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 90 of 163JJVC CONFIDENTIAL
Example 2
Manifest (spectacle) refraction:O.D. -3.00D / -1.00D x 90° 20/20O.S. -4.75D / -2.00D x 90° 20/20
Choose diagnostic lenses of -3.00D / -0.75D x 90° for the right 
eye and -4.50D / -1.75D x 90° for the left eye, the nearest lenses available to the spherical power, cylinder power, and axis needed. For the left eye, since the manifest refraction called for -4.75D, compensating for vertex distance the sphere is reduced by 0.25D to -4.50D. The cylinder power will be -1.75D. Place the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient's initial response to the lens. If the lens has not yet stabilized, recheck until stable. 
Right Eye
The orientation mark on the right lens rotates left from the 6 
o’clock position by 10° and remains stable in this position. Compensation for this rotation should be done as follows: 
Compensate the 10° axis drift by adding it to the manifest 
refraction axis.
Here is the Rx Prescribed:
O.D. -3.00D / -0.75D x 100°
Left Eye
The orientation mark on the left lens rotates right from the 6 
o’clock position by 10° and remains stable in this position. 
Compensate for the 10° axis drift by subtracting it from the 
manifest refraction axis. 
Here is the Rx Prescribed: 
O.S. -4.50D / -1.75D x 80°
If vision is acceptable, perform a slit lamp examination to assess 
adequate ﬁ  t (centration and movement). If ﬁ  t is acceptable, dispense the lenses instructing the patient to return in one week for reassessment (see dispensing and follow-up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 91 of 163JJVC CONFIDENTIAL
MONOVISION FITTING GUIDELINES
A. Patient Selection
1. Monovision Needs Assessment
For a good prognosis, the patient should have adequately 
corrected distance and near visual acuity in each eye. The amblyopic patient or the patient with signiﬁ  cant astigmatism (greater than 1.00D) in one eye may not be a good candidate for monovision correction with these lenses.
Occupational and environmental visual demands should be 
considered. If the patient requires critical vision (visual acuity and stereopsis), it should be determined by trial whether this patient can function adequately with monovision correction. Monovision contact lens wear may not be optimal for activities such as:
• visually demanding situations such as operating potentially 
dangerous machinery or performing other potentially hazardous 
activities; and
• driving automobiles (e.g., driving at night). Patients who cannot 
meet state driver's licensing requirements with monovision correction should be advised to not drive with this correction, OR may require that additional over-correction be prescribed.
2. Patient Education
All patients do not function equally well with monovision correc-tion. Patients may not perform as well for certain tasks with this correction as they have with spectacles (multifocal, bifocal, trifocal, readers, progressives). Each patient should understand that monovision, as well as other presbyopic alternatives, can create a vision compromise that may reduce visual acuity and depth perception for distance and near tasks. Therefore, caution should be exercised when the patient is wearing the correction for the ﬁ  rst time until they are familiar with the vision provided in visually chal-lenging environments (e.g., reading a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). During the ﬁ  tting process, it is necessary for the patient to realize the disadvantages as well as the advantages of clear near vision and straight ahead and upward gaze that monovision contact lenses provide.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 92 of 163JJVC CONFIDENTIAL
B. Eye Selection
1. Ocular Preference Determination Methods
Generally, the non-dominant eye is corrected for near vision. The 
following two methods for eye dominance can be used.
Method 1:  Determine which eye is the “sighting eye.” Have the 
patient point to an object at the far end of the room. 
Cover one eye. If the patient is still pointing directly at the object, the eye being used is the dominant (sighting) eye.
Method 2:  Determine which eye will accept the added power with 
the least reduction in vision. Place a hand-held trial lens equal to the spectacle near ADD in front of one eye and then the other while the distance refractive error correction is in place for both eyes. Determine whether the patient functions best with the near ADD lens over the right or left eye.
2. Other Eye Selection Methods
Other methods include the "Refractive Error Method" and the "Visual Demands Method."
Refractive Error MethodFor anisometropic correction, it is generally best to ﬁ  t the more 
hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.
Visual Demands Method
Consider the patient’s occupation during the eye selection process 
to determine the critical vision requirements. If a patient’s gaze for near tasks is usually in one direction, correct the eye on that side for near.
Example: A secretary who places copy to the left side of the desk 
will function best with the near lens on the left eye.
C. Special Fitting Characteristics
1. Unilateral Vision Correction
There are circumstances where only one contact lens is required. As an example, an emmetropic patient would only require a near lens, whereas a bilateral myope would require corrective lenses on Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 93 of 163JJVC CONFIDENTIAL
both eyes.
Examples: A presbyopic emmetropic patient who requires a +1.75D ADD 
would have a +1.75D lens on the near eye and the other eye left without correction. 
A presbyopic patient requiring a +1.50D ADD who is -2.50D 
myopic in the right eye and -1.50D myopic in the left eye may have the right eye corrected for distance and the left uncorrected for near.
2. Near ADD Determination
Always prescribe the lens power for the near eye that provides optimal near acuity at the midpoint of the patient’s habitual reading distance. However, when more than one power provides optimal reading performance, prescribe the least plus (most minus) of the powers.
3. Trial Lens Fitting
A trial ﬁ  tting is performed in the ofﬁ  ce to allow the patient to experience monovision correction. Lenses are ﬁ  t according to the GENERAL FITTING GUIDELINES for base curve selection described in this Package Insert.
Case history and standard clinical evaluation procedure should 
be used to determine the prognosis. Determine the distance correction and the near correction. Next determine the near ADD. With trial lenses of the proper power in place, observe the reaction to this mode of correction.
Allow the lenses to settle for about 20 minutes with the correct 
power lenses in place. Walk across the room and have the patient look at you. Assess the patient’s reaction to distance vision under these circumstances. Then have the patient look at familiar near objects such as a watch face or ﬁ  ngernails. Again assess the reaction. As the patient continues to look around the room at both near and distance objects, observe the reactions. Only after these vision tests are completed should the patient be asked to read print. Evaluate the patient’s reaction to large print (e.g., typewritten copy) at ﬁ  rst and then graduate to newsprint and ﬁ  nally smaller type sizes.
After the patient’s performance under the above conditions 
is completed, tests of visual acuity and reading ability under Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 94 of 163JJVC CONFIDENTIAL
conditions of moderately dim illumination should be attempted.
An initial unfavorable response in the ofﬁ  ce, while indicative of 
a guarded prognosis, should not immediately rule out a more extensive trial under the usual conditions in which a patient functions.
4. Adaptation
Visually demanding situations should be avoided during the initial wearing period. A patient may at ﬁ  rst experience some mild blurred vision, dizziness, headaches, and a feeling of slight imbalance. You should explain the adaptational symptoms to the patient. These symptoms may last for a brief minute or for several weeks. The longer these symptoms persist, the poorer the prognosis for successful adaptation.
To help in the adaptation process, the patient can be advised to 
ﬁ  rst use the lenses in a comfortable familiar environment such as in the home.
Some patients feel that automobile driving performance may not 
be optimal during the adaptation process. This is particularly true when driving at night. Before driving a motor vehicle, it may be recommended that the patient be a passenger ﬁ  rst to make sure that their vision is satisfactory for operating an automobile. During the ﬁ  rst several weeks of wear (when adaptation is occurring), it may be advisable for the patient to only drive during optimal driving conditions. After adaptation and success with these activities, the patient should be able to drive under other conditions with caution.
D. Other Suggestions
The success of the monovision technique may be further improved by having the patient follow the suggestions below:
• Have a third contact lens (distance power) to use when critical 
distance viewing is needed.
• Have a third contact lens (near power) to use when critical near 
viewing is needed.
• Having supplemental spectacles to wear over the monovision 
contact lenses for speciﬁ  c visual tasks may improve the success of monovision correction. This is particularly applicable for those patients who cannot meet state driver's licensing requirements with monovision correction.
• Make use of proper illumination when carrying out visual tasks.Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 95 of 163JJVC CONFIDENTIAL
Monovision ﬁ  tting success can be improved by the following 
suggestions:
• Reverse the distance and near eyes if a patient is having trouble 
adapting.
• Reﬁ  ne the lens powers if there is trouble with adaptation. 
Accurate lens power is critical for presbyopic patients.
• Emphasize the beneﬁ  ts of clear near vision and straight ahead 
and upward gaze with monovision.
The decision to ﬁ  t a patient with monovision correction is most appropriately left to the Eye Care Professional in conjunction with the patient after carefully considering the patient’s needs.
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
PATIENT MANAGEMENT
Dispensing Visit
Each sterile lens is supplied in a foil-sealed plastic package containing 
buffered saline solution with methyl ether cellulose. To remove the lens from the container, peel back the foil seal, place a ﬁ  nger on the lens, and slide the lens up the side of the bowl of the lens package until it is free of the container.
• Evaluate the physical ﬁ  t and visual acuity of the lens on each eye.
• Teach the patient how to apply and remove his or her lenses.
• Explain daily disposable lens wear and schedule a follow-up examination.
• Provide the patient with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
REVIEW THESE INSTRUCTIONS WITH THE PATIENT SO THAT HE 
OR SHE CLEARLY UNDERSTANDS THE PRESCRIBED WEARING AND REPLACEMENT SCHEDULES.
Follow-Up Examinations
Follow-up care (necessary to ensure continued successful contact lens wear) should include routine periodic progress examinations, management of speciﬁ  c problems, if any, and a review with the patient of the wear schedule, daily disposable modality, and proper lens handling procedures. Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 96 of 163JJVC CONFIDENTIAL
Recommended Follow-up Examination Schedule (complications 
and speciﬁ  c problems should be managed on an individual patient 
basis):
1. One week from the initial lens dispensing to patient
2. One month post-dispensing
3. Every three to six months thereafter 
NOTE: Preferably, at the follow-up visits, lenses should be worn for at least 
six hours.
Recommended Procedures for Follow-up Visits:
1. Solicit and record patient’s symptoms, if any.
2. Measure visual acuity monocularly and binocularly at distance and 
near with the contact lenses.
3. Perform an over-refraction at distance and near to check for residual 
refractive error.
4. With the biomicroscope, judge the lens ﬁ  tting characteristics (as 
described in the GENERAL FITTING GUIDELINES) and evaluate 
the lens surface for deposits and damage.
5. Following lens removal, examine the cornea and conjunctiva with 
the biomicroscope and ﬂ  uorescein (unless contraindicated).
• The presence of vertical corneal striae in the posterior central 
cornea and/or corneal neovascularization is indicative of 
excessive corneal edema.
• The presence of corneal staining and/or limbal-conjunctival 
hyperemia can be indicative of an unclean lens, a reaction to solution preservatives, excessive lens wear and/or a poorly ﬁ  tting lens.
• Papillary conjunctival changes may be indicative of an unclean 
and/or damaged lens.
6. Periodically perform keratometry and spectacle refractions. The 
values should be recorded and compared to the baseline meas-
urements.
If any observations are abnormal, use professional judgment to 
alleviate the problem and restore the eye to optimal conditions. If Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 97 of 163JJVC CONFIDENTIAL
the criteria for successful ﬁ  t are not satisﬁ  ed during any follow-up 
examinations, repeat the patient’s trial ﬁ  tting procedure and reﬁ  t 
the patient.
WEARING SCHEDULE
The wearing schedule should be determined by the Eye Care Professional.   
Regular checkups, as determined by the Eye Care Professional, are also extremely important.
Patients tend to overwear the lenses initially. The Eye Care Professional 
should emphasize the importance of adhering to the initial maximum wear-ing schedule.  Maximum wearing time should be determined by the Eye Care Professional based upon the patient’s physiological eye condition, because individual response to contact lenses varies.
The maximum suggested wearing time for these lenses is:
Day Hours
1 6-8
2 8-10
3 10-12
4 12-14
5 and after all waking hours
REPLACEMENT SCHEDULE
These lenses are indicated for daily disposable wear and should be 
discarded upon removal.
LENS CARE DIRECTIONS
When lenses are prescribed for daily disposable wear, the Eye Care Professional should provide the patient with appropriate and adequate warnings and instructions for daily disposable lens wear at the time they are dispensed. Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 98 of 163JJVC CONFIDENTIAL
The Eye Care Professional should review with patients that no cleaning 
or disinfection is needed with daily disposable lenses. Patients should always dispose of lenses when they are removed and have spare lenses or spectacles available.
Basic Instructions
• Always wash, rinse, and dry hands before handling contact lenses.
• Do not use saliva or anything other than the recommended solutions 
for lubricating or rewetting lenses. Do not put lenses in the mouth.
• Eye Care Professionals may recommend a lubricating/rewetting solution which can be used to wet (lubricate) lenses while they are being worn to make them more comfortable. 
Care for a Sticking (Non-Moving) Lens
If the lens sticks (stops moving), the patient should be instructed to apply 
a few drops of the recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to move freely on the eye before removing it. If non-movement of the lens continues after a few minutes, the patient should immediately consult the Eye Care Professional.
EMERGENCIES
The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY WITH TAP WATER AND IMMEDIATELY CONTACT THE EYE CARE PROFESSIONAL OR VISIT A HOSPITAL EMERGENCY ROOM WITHOUT DELAY. 
HOW SUPPLIED
Each UV-blocking sterile lens is supplied in a foil-sealed plastic package containing buffered saline solution with methyl ether cellulose. The plastic package is marked with the following: 
• ACUVUE OASYS
® 1-Day: base curve, power, diameter, lot number, 
and expiration date
• ACUVUE OASYS® 1-Day for ASTIGMATISM: base curve, power, 
diameter, cylinder, axis, lot number, and expiration dateClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 99 of 163JJVC CONFIDENTIAL
REPORTING OF ADVERSE REACTIONS
All serious adverse experiences and adverse reactions observed in 
patients wearing these lenses or experienced with these lenses should be reported to:
Johnson & Johnson Vision Care, Inc.
7500 Centurion Parkway
Jacksonville, FL 32256
USA
Tel: 1-800-843-2020
www.acuvue.comClinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 100 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
APPENDIX D:   
x LENS FITTING CHARACTERISTICS 
x SUBJECT REPORTED OCULAR SYMPTOMS 
x DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS  
x BIOMICROSCOPY SCALE  
x DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
x TORIC FIT EVALUATION 
x ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE 
x PATIENT REPORTED OUTCOMES 
x LENS INSERTION AND REMOVAL 
x VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING 
CR-6482, v 2.0  
Page 102 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 LENS FITTING CHARACTERISTICS 
 
 
  
CR-6482, v 2.0  
Page 103 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 SUBJECT REPORTED OCULAR SYMPTOMS 
 
  
CR-6482, v 2.0  
Page 109 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 DETERMINATION OF DIST ANCE SPHEROCYLINDRICAL 
REFRACTIONS 
 
  
CR-6482, v 2.0  
Page 111 of 163JJVC CONFIDENTIAL
Title:                           De termination of Distance Spherocylindrical Refractive Error
Document Type:  
Document Number: Revision Number:  5 
   Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 113 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 BIOMICROSCOPY SCALE  
 
 
  
CR-6482, v 2.0  
Page 117 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
 
  
CR-6482, v 2.0  
Page 123 of 163JJVC CONFIDENTIAL
Title:                          Distance and Near Snelle n Visual Acuity Evaluation
Document Type:  
Document Number: Revision Number:  5 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 125 of 163JJVC CONFIDENTIAL
Title:                          Distance and Near Snelle n Visual Acuity Evaluation
Document Type:  
Document Number: Revision Number:  5 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 127 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 TORIC FIT EVALUATION 
 
  
CR-6482, v 2.0  
Page 128 of 163JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number: Revision Number:  7 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 130 of 163JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number: Revision Number:  7 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 132 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE 
 
  
CR-6482, v 2.0  
Page 133 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
PATIENT REPORTED OUTCOMES 
  
CR-6482, v 2.0  
Page 137 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 LENS INSERTION AND REMOVAL 
 
  
CR-6482, v 2.0  
Page 139 of 163JJVC CONFIDENTIAL
Title:     Lens Insertion and Removal
Document Type:
Document Number: Revision Number:  3 
  
   
  Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 141 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
 VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING 
  
CR-6482, v 2.0  
Page 142 of 163JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 144 of 163JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 145 of 163JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 146 of 163JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 148 of 163JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 149 of 163JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.
CR-6482, v 2.0  
Page 150 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
APPENDIX E: GUIDELINES FOR COVID-19 RISK MITIGATION   
  
CR-6482, v 2.0  
Page 151 of 163JJVC CONFIDENTIAL
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE 
Protocol Number and Title: CR-6482 Feasibility Eval uation of Daily Disposable Toric Soft Contact 
Lenses Manufactured with an Alternative Hydration Process 
 
Version and Date: 2.0 27 June 2022 
 
I have read and understand the protocol specified above and agree on its content.   
 I agree to conduct this study according to ISO 14155:2020,
1 GCP and ICH guidelines,2 the Declaration 
of Helsinki,3 United States (US) Code of  Federal Regulations (CFR),4 and the pertinent individual 
country laws/regulations and to comply with its obligations, subject to ethical and safety considerations. 
The Principal Investigator is responsible for ensuring that all clinical site personnel, including Sub-
Investigators adhere to all ICH2 regulations and GCP guidelines regarding clinical trials during and 
after study completion. 
 I will assure that no deviation from or changes to the protocol will take place without prior agreement 
from the Sponsor and documented approval from the Institutional Review Board (IRB), except where 
necessary to eliminate an immediate hazard(s) to the trial participants. 
 
I am responsible for ensuring that all clinical site personnel including Sub-Investigators adhere to all ICH
2 regulations and GCP guidelines regarding clinical trials during and after study completion. 
 All clinical site personnel involved in the conduct of this study have completed Human Subjects 
Protection Training.  
 I agree to ensure that all clinical site personnel involved in the conduct of this study are informed about 
their obligations in meeting the above commitments. 
 
I shall not disclose the information contained in this protocol or any results obtained from this study 
without written authorization.  
I have read the suggested guidance provided by JJVCI pertaining to the COVID-19 risk mitigation, 
(COVID-19 Work Instruction in the Appendix E of th is protocol). I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID-19 risks.  
Principal 
Investigator:    
 Signature 
 
  Date 
 Name and Professional Position (Printed)   
 
Institution/Site:     
 Institution/Site Name 
 
  
  
 Institution/Site Address   
 
CR-6482, v 2.0  
Page 163 of 163JJVC CONFIDENTIAL